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Executive summary 
 
Background 
The Khartoum State Revolving Drug Fund (RDF) is a cost-sharing mechanism which takes 
advantage of people’s ability and willingness to pay for drugs in the absence of free state 
provision.  In Sudan, the RDF was established by the Khartoum Ministry of Health (KMoH) 
and Save the Children UK (SC UK) at a time when federal and state funding was minimal.  
The RDF addressed the three core issues of quality, supply and cost of drugs.  Prior to the 
establishment of the RDF, the quality and supply of drugs was inadequate for the population, 
and the cost was perceived to be prohibitive for most people.  Previous evaluations of the 
RDF have found it to be successful in bringing down the cost of drugs to around 50% that of 
private pharmacies and achieving a good standard of quality and a reliable supply.   
 
This study was commissioned to investigate whether the RDF is continuing to fulfil its original 
mandate, nearly a decade after hand-over by SC UK, and three years after becoming an 
independent foundation. The researchers were asked to focus on three aspects: the on-
going sustainability of the RDF; whether it continues to supply safe and appropriate drugs at 
below market prices; and issues of access, which had not been examined in depth by 
previous studies. 
 
Study methods 
There were nine different components to this study: 
 literature review, to examine the RDF’s history and also to fit the study  findings into the 
context of wider developments in Sudan and internationally 
 interviews with key informants in Khartoum, to assess the policy context and to pick up 
concerns and suggestions for potential improvements to the RDF 
 household economy approach (HEA) study of different areas within the State, focussing 
on household livelihoods and coping strategies, and hence ability to afford health care 
and other basic goods 
 household survey focussing on health seeking behaviour, expenditure on health care, 
coping strategies, and perceptions of health facilities and the RDF  
 focus group discussions (FGD), which used qualitative techniques to probe similar 
questions 
 health facility survey, which looked at prescribing practices and indicators of quality of 
care within RDF outlets 
 financial analysis of the RDF, to focus on profitability, operating costs, financial 
management and probity 
 pharmaceutical study, to look at issues of quality, pricing, procurement, management and 
the range of drugs which the RDF currently supplies 
 management study, focussing on the structure of the RDF, its human resource policies, 
management issues and legal status 
 
Study findings 
 
How the RDF is working at present - strengths and weaknesses 
 
This evaluation concludes that the RDF is continuing to fulfil its original mandate, to provide a 
sustainable source of appropriate, quality drugs at below-market price levels.  
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Its strengths can be summarised as follows: 
 It continues to serve the majority of the KMoH network of health centres and hospitals in 
Khartoum State, as well as 18 of the People’s Pharmacies  
 Its price list undercuts rivals by 40% (CMSPO) and 100% (People’s Pharmacies and 
private pharmacies), on average 
 It operates a unitary system, offering the same price to all public facilities, and absorbing 
the financial risks (the RDF sells directly to patients, not to the facilities, except for the 
People’s Pharmacies) 
 It maintains regular supervision and deliveries: drugs availability is good at facility level 
 It offers a wide range of drugs (145 items in total) 
 Assessment of selected rational drug use indicators showed the proportion of patients 
encounters using one or more injection and the number of drugs prescribed per patient to 
be within or very close to optimal levels. 
 It is profitable: gross profits have been rising year on year due to large increases in 
volume of drugs sales 
 The financial review suggests that internal control systems are good 
 Its ratio of assets to liabilities is healthy 
 It has just been through a period of capital expansion, investing in a new office building 
and warehouse 
 Foreign currency availability is no longer a constraint, given the wider economic changes 
in Sudan 
 It makes a regular transfer to the KMoH, worth 210 million SDD per year, which more 
than outweighs the fiscal subsidy of its 17.5% customs tax exemption 
 It offers other public services, such as delivering emergency drugs and vaccines 
 
Set against this are some areas of weakness, or concerns: 
 Profit levels are high; this, while a good thing from a business point of view, may indicate 
that prices to users could be reduced 
 Operating costs have increased substantially in the RDF in 2001-3, especially in the area 
of salaries and incentives 
 The value of expired stock has also increased significantly over this period 
 The build up of stocks means that the working capital cycle has doubled between 2001 
and 2003, which increases the risk of losses 
 The value of debts, particularly from one or two non-paying specialist hospitals, threatens 
the RDF’s ability to pay creditors, which is essential for its continued smooth procurement 
(though this situation is now being improved). 
 Decreases in attendances at RDF facilities and problems with the health insurance 
system have resulted in reduced profits for the past three years. This is a worrying trend. 
 The proportion of RDF sales value which is being transferred to the KMoH has doubled 
over time (at the same time as KMoH contributions, in form of staff salaries, for example, 
have reduced). It is now 17.5 million SDD each month. Excessive extraction is a threat to 
the RDF’s viability. It is also not clear whether the surplus is being used according to the 
originally agreed purpose of promoting PHC. 
 An absence of capital investment plans is noted, particularly in relation to the current 
development of new offices 
 There is a need for more details in the recent financial reports, including giving 
explanations for trends 
 The RDF has suffered from an unfortunate discontinuity of management over the past 
two years, though a permanent director has now been appointed in 2005. Strong 
leadership is essential to continued viability and quality of work. 
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 The RDF’s fortune is now strongly connected with the KHIC, which is its major purchaser. 
It also owns shares in the KHIC. Any adverse development for the KHIC would also 
impact on the RDF. It is also dependent for its current profits on its People’s Pharmacy 
network: through 18 outlets it sells more drugs than through its 123 hospitals and health 
centres. 
 Linked to that is the disproportionate growth in sales of non-essential drugs. While driving 
up profits, there is a real risk that the RDF mandate of promoting rational prescribing will 
be overshadowed by this trend. 
 The prescription review suggests that antibiotics use is still too high and has risen since 
the last survey (in 2000). That and the high use of syrups and low use of ORS suggest 
that there is need for more investment in practitioner and consumer education 
 Qualitative information from focus groups show that patient awareness is also low  
 Although availability of essential drugs is still high in facilities, it has dropped from 100% 
in previous surveys to 95% now. 
 The market survey found that for the 15 most commonly used drugs, the CMSPO prices 
undercut the RDF’s – on average by 10%. (Note though that the CMSPO does not sell 
direct to the public: retailers will add 20-35% to these prices, whereas, at least for the 
health centres and hospitals, RDF prices are the prices that users pay.) 
 Although the RDF is supposed to operate a fixed price list, small but significant variations 
in prices were found across the facilities (not correlated to location or any other variable) 
 Poor stock keeping records were found in the health facility survey 
 Public awareness of the RDF and public involvement in CHCs was found to have 
remained at a low level 
 Operations research, which was once seen as a core activity for the RDF, appears to 
have withered 
 
Who is benefiting? 
 
As the RDF operates through all of the main KMoH health centres and hospitals in KS, the 
question of who is benefiting has to be answered by looking at use of the public facilities in 
general. 
 
Overall utilisation trends for the RDF network are positive, rising to 3 out of the 5 million 
people in 2002, though with a small decrease the following year.  
 
Geographic access to the facilities is good: mean time to reach a health centre in the 
household survey was 15 minutes, and 34 to reach a public hospital.  
 
Quality indicators examined in the health facility survey are on the whole positive and 
suggest that quality does not vary systematically by location or rural/urban status, with the 
exception of KMoH supervision, which is more frequent in urban areas. (The full details of the 
health facility findings are published separately (Cadge, N. & Elkarim, Professor M., 2005)). 
 
The household survey also reinforces the importance of the public services: the main 
treatment strategy was to go to a health centre (36% overall), followed by public hospitals 
(29% overall). Moreover, these facilities are more important for the poor: use of health 
centres is concentrated in the bottom three quintiles, while hospitals are important to the 
bottom four quintiles, but not the richest. 
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Financial barriers are, however, significant. Since the liberalisation and health sector reforms 
of the 1990s, Sudan has placed a heavy burden of paying for health care on households, 
with the state contributing a mere 20% (one of the lowest proportions in Africa). Of these 
household costs, drugs form 58% of the total, according to our household survey. 
 
According to the HEA, 17% of Khartoum State’s population is unable to afford basic health 
care for all or part of the year. This group is concentrated in the IDPs – 60-75% of IDP 
households fall into this category, compared with 5-10% for the rural and urban poor. A 
further 24% overall is estimated to be unable to afford emergency health care without 
assistance (22% in urban areas; 30% in IDP areas; and 30% in rural areas). 
 
In the household survey, 6% opted for no treatment (with lack of money the predominant 
factor), while 29% of those who sought treatment could not afford to pay for it. For the more 
disadvantaged groups, inability to pay is, of course, higher: within IDP areas, 46.5% could 
not afford to pay, while for the bottom quintiles, the proportion is 32-37%. Moreover, 
households in the poorest quintile are five times more likely not to treat sick members, 
compared with the top quintile.  
 
Overall, health expenditure as a proportion of household income is 11%, which is high by 
international standards. The differences between areas were not statistically significant, but 
the group with the highest proportion were the IDPS, who were found to be spending 15% of 
their total household income on health care. 
 
For those who cannot afford to pay, borrowing is the main coping strategy across the social 
groups (57% overall), which reinforces qualitative information on the importance of informal 
social networks. 
 
Formal support systems were found to exist, but to be limited in scale, arbitrary and difficult 
to access. Exemptions policies vary by facility and only 1% reported receiving them. 3% of 
those who were unable to pay reported receiving charitable donations and 3% reported 
assistance from the Zakat (the official Muslim social support fund). FGDs reported bias in 
allocating assistance from the Zakat, favouring those with better contacts.  
 
Options for expanding access within Khartoum 
 
Given that the main barriers to accessing the RDF are financial, any measure which reduces 
household costs (for vulnerable groups) or increases their income will increase access. The 
potential range of actions is therefore wide. 
 
Providing internal subsidies within the RDF is one option, but given the need for the RDF to 
maintain its viability, there is limited scope for this. Besides, the aim should be to increase 
access to health care generally, rather than encouraging self-prescription. It is therefore 
preferable to extend health insurance cover to those who cannot currently afford to access 
basic care. The health insurance network and quality is adequate, and this measure would 
boost its development, as well as increasing business for the RDF, at low administrative 
costs. 
 
Given current Khartoum Health Insurance Corporation (KHIC) premia, to provide 
membership for 20% of KS population would cost in the region of USD 3 million per year. 
This could be funded from a number of sources, including State budgets; the RDF ‘surplus’, 
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which it pays monthly to the KMoH; the Zakat (which does fund some poor households to 
join at present, but on a limited scale); and aid flows, which should increase post-peace 
agreement. Identification of beneficiaries could be carried out using the HEA information. 
 
Given that so many of the households which are excluded are IDP2 ones, an alternative 
would be to restart the free services which used to exist in IDP areas, but which were closed 
earlier this decade, once conditions were thought to have improved. (This will prove complex 
if IDPs are dispersed amongst the host community, however.) 
 
Another option which would assist both IDPs and other poor and vulnerable residents would 
be to improve the administration of the Zakat, so that it becomes available on a larger scale, 
with clear criteria for access, lower access costs, and greater transparency and 
accountability. 
 
‘Peace dividend’ funds should also be used to increase the overall public contribution to 
health care and so enable user fees in public facilities to be reduced. Some areas could be 
declared exempt as a region, on the basis of widespread poverty. Closer analysis of health 
spending at all levels would also identify areas where resources could be shifted to increase 
equity and efficiency. There is more detail on these recommendations in our household 
survey report (Witter, S. & Babiker, M., 2005).  
 
Other measures to support the income of vulnerable groups include: changes to the 
replanning process, to reduce costs for IDPs; income generation activities aimed at boosting 
and diversifying income in IDP areas; and development of infrastructure in outlying areas 
(rural as well as IDP settlements) to enhance access to markets. The HEA report provides 
more detailed recommendations on these areas (Adams, L. & et al., 2004). 
 
Issues for national expansion 
 
Lessons for other areas of Sudan are limited, in that the data gathered here cannot be taken 
as representative outside Khartoum State, given the large differences in infrastructure and 
income levels. However, the general evidence suggests that RDFs, run along similar lines to 
the Khartoum RDF, could be equally successful in richer states, while free drug distribution 
programmes are more realistic for the more remote and poorer states. 
 
Given the interest in expanding the RDF model to other States, a systematic evaluation of 
the CMSPO roll-out to date should be conducted. This is the second attempt, in that Bamako 
Initiative-style drug funds were set up at local level in the 1990s. Documentation of that 
experience is also lacking. 
                                               
2
 IDPs are families who have fled from conflict and economic hardship, mainly in the south and west of 
Sudan, to live in the Khartoum area. Although many have been there for two decades, they continue 
to be classified as IDPs. In the wake of the Comprehensive Peace Agreement in 2005, many are 
returning to their home areas, particularly in the south. It is not clear how many of the 2 million will 
remain as residents of Khartoum State. 
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Recommendations 
 
The RDF should continue to provide its services for Khartoum and to enjoy political support 
and independent status. However, there are significant findings which need to be acted on, 
internally and externally. 
 
Recommendations for the RDF management  
 
The policy on salaries and incentives needs to be reviewed, so that this type of expenditure 
does not spiral out of control. 
 
The RDF management should investigate the causes behind the following issues which have 
been raised, and demonstrate how it is addressing them: 
 Increase in expired stocks in facilities 
 Poor stock record keeping in some facilities 
 Fall in availability of essential drugs  
 Small but significant variation in prices charged for drugs by facilities 
 
The policy of subsidising more expensive drugs should be reviewed: what are the equity 
implications of this? 
 
The management should discuss an informal cap on gross profits at around 15%, to 
minimise costs to users while maintaining adequate funds for reinvestment. (This cap could 
be lifted for exceptional circumstances, such as infrastructure expansion, but would be 
regarded as a norm, with justification required for increases.) 
 
In addition to providing routine data, the RDF should focus on questions of importance for its 
overall function and carry out appropriate action research relating to these. These need not 
be ambitious or expensive, but would encourage a culture of reflection and goal-orientation: 
the RDF should continue to see itself as more than a business - as a role to pay in promoting 
good health generally. 
 
Related to that is the need for renewed practitioner and client education on rational drugs 
use (in particular, to reduce the proportion of antibiotics being prescribed). This should be 
carried out in partnership with the KMoH Department of Pharmacy and the KHIC. Financial 
incentives to increase sales should be reviewed to ensure that they do not promote irrational 
prescribing. In this respect, it would be worth monitoring the proportion of essential/non-
essential sales through People’s Pharmacies, as well as keeping a downward pressure on 
the sale of brand name drugs through these channels. The public demand and growth in 
insured patients is creating an upward pressure on expenditure, which is not in the public 
interest. 
 
The RDF and KMoH should together develop a plan to address the drugs supply to smaller, 
more remote health centres. This may require some medication of the RDF’s systems – for 
example, by allowing longer intervals between supply and supervision visits.  
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The RDF should review its procurement practice, to ensure that it is getting the right balance 
of quality and price. 
 
The relationship with non-paying debtors, such as the Cardiac Unit, which is in the process of 
being resolved, should not be allowed to recur. 
 
The donated fixed assets should be re-valued, included in the financial records, and 
depreciated on an annual basis. 
 
Format of annual financial statements must continue to be in accordance with the 
international accounting standards and reporting standards, and approved by all the 
stakeholders. 
 
Ministry of Health 
 
The KMoH should review the amounts that it is being paid monthly by the RDF: the current 
level seems unduly high and may be one of the factors behind the build up of creditors. 
Moreover, the basis for payment was that the RDF was using and benefiting from KMoH 
facilities. If, as has been the case recently, the RDF is asked to shoulder the cost of 
constructing new pharmacies for public facilities, then the rationale for the transfer no longer 
remains. 
 
The KMoH should investigate the causes behind the documented drop in supervision, 
especially to rural health centres, and other quality issues raised in the health facility report. 
 
The low levels of utilisation of public facilities documented in the health facility report and 
also indicated in the declining attendances at RDF facilities (other than PPs) should also be 
addressed in partnership by the RDF and KMoH. Strategies here could include 
improvements in hours worked by health staff and public education on the efficacy of generic 
drugs. 
 
The user fee tariff should be made flatter and more transparent, with better posting of prices 
in health facilities. 
 
The KMoH should work with the FMoH to ensure that additional barriers to importation and 
clearance of drugs are not created and that the RDF is facilitated in carrying out its work 
efficiently. 
 
There is a need for the FMoH and KMoH to review the NEDL, to ensure that it is up-to-date 
with current prescribing practice. 
 
 
Government and donors 
 
The burden of paying for health care falls heavily on households at present in Sudan, 
compared with other developing countries. The GoS should use ‘peace dividend’ funds to 
increase its overall contribution to health care, thus reducing the burden of cost recovery, 
particularly in the poorer States. 
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Donors should study the case for reinstating free programmes, which used to benefit 
vulnerable groups, such as the IDPs in Khartoum State. 
 
Measures to support IDP incomes and access to infrastructure should be taken to improve 
access to health care, among other goods. 
 
The operation of the Zakat needs to be reviewed: it is currently viewed as ineffectual due to 
complex procedures, perceived favouritism, and lack of transparency. 
 
Measures to improve access to health care and drugs should include the provision of KHIC 
membership to vulnerable households in Khartoum State.  
 
Further research is needed to for health financing in Sudan generally, as well as more 
specifically on expenditures at State level and the operation of RDFs outside Khartoum. 
These will inform decisions on the overall budget for health and also maximising the use of 
existing resources. 
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BACKGROUND 
 
1. Introduction 
 
History of the RDF 
 
The Revolving Drug Fund (RDF) was jointly initiated by the Khartoum Ministry of Health 
(KMoH) and Save the Children UK in the mid-1980s, though it took until 1989 for the first 
drugs to be supplied to health centres. It arose out of recognition of the weakness of the 
primary care system in the state and the increasing number of common childhood illnesses 
being brought to the Children’s Emergency Hospital. The RDF was developed as part of a 
wider project - the Khartoum Comprehensive Child Care project (KCCCP), which aimed to 
revitalise primary health care services through improved drug supplies, equipment, staff 
training, refurbishment of health centres, and improving primary health care systems.  
 
The RDF component aims were: 
 To increase access to essential drugs at affordable prices 
 To encourage the rational use of drugs 
 
The first was to be achieved by setting up a sustainable drug revolving fund, with full cost 
recovery (but no subsidy to external activities, as was practiced by the Bamako Initiative). 
The second was to be achieved by investment in infrastructure, training and operational 
research. 
 
The importance of financing strategies for drugs is underlined by the fact that, generally 
speaking, developing countries spend a much higher proportion of their total health spending 
on drugs (24-66%), compared to 7-20% for developed countries (Quick, J., 2000)). In 
addition, the public spending on drugs, as a proportion of total drug expenditure, is typically 
much lower in developing countries (5-50%), compared with developed countries (50-90%), 
leaving a heavy financial burden on households. Studies in Sudan and elsewhere confirm 
that the availability of drugs is often seen as the key indicator of quality of health care by 
households (Habbani, K., Groot, W., & Jelovac, I., 2005). 
 
A project implementation committee was established, representing Save the Children UK 
and the KMoH. Members included the KCCCP director, the Director General of Health, 
pharmacy staff, district health directors, financial staff, the project coordinator and project 
pharmacist (the latter two Save the Children UK staff). 
 
The RDF imports drugs from non-profit suppliers abroad, or from local sources, where these 
are available. A committee made up of RDF management and PHC representatives selects 
the drugs from the Sudan Essential Drugs List. These are then sold on at cost, plus a mark-
up to cover overall running costs (including reserves against devaluation etc.). Cross-
subsidies are operated from the common, cheaper drugs to some of the more expensive 
ones. Prices for patients are uniform across the State: there is therefore some cross-subsidy 
from the closer facilities to the more remote ones, which are more expensive to supply and 
supervise. 
 
Drugs are delivered to RDF-supported pharmacies in the health facilities, based on previous 
consumption patterns. Funds are collected monthly, against sales records. (For a more 
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detailed description of the operation of the RDF, see (Gamaleldin Khalafalla Mohamed Ali, 
2000)). An important point is that the RDF does not sell to the health centres to sell on (which 
would place the financial risk on the health centre), but sells directly to the patients, via 
pharmacies in health centres and hospitals. 
 
Starting with 13 health centres in 1989, the RDF expanded to 77 outlets (65 health centres 
and 12 rural hospitals) by 1996. The list of essential drugs also expanded from 70 to 90 
items. $1.8 million was invested in capitalising these outlets. Save the Children UK also 
provided training, refurbished pharmacies and provided transport until the programme was 
handed over in 1996 to the KMoH (Tembon, Chi Andy, 1996).  
 
An evaluation of the overall KCCCP carried out in 1996 (AwadElKarim, Professor M. A., 
1996) concluded that the RDF ‘was able to improve the supply system and avail a range of 
essential drugs at affordable prices’. It also noted improvements in rational prescribing, 
though ‘efforts are still needed for further improvements in this area’. It found that 8% of 
patients were unable to pay for the prescription cost. (This was based on the proportion of 
prescriptions where the drugs were available, but were not dispensed.) It noted that the RDF 
policy of cost recovery had since become a key government policy in health, throughout the 
country, and recommended that the RDF model be expanded nationwide. 
 
During the next phase, 1996-2002, the RDF became an independent project within the 
KMoH. Changes over this period included the following: 
 Financial incentives were introduced to retain staff 
 Training programmes were organised for all members of staff, including raising external 
funds for 25 Masters degrees and 25 short courses abroad for pharmacists working in 
headquarters and health facilities 
 A new employment contract was signed with pharmaceutical staff, whereby they would 
have to pay for stock losses. This reduced the leakage of drugs 
 Management improvements included a system for reconciling cash with the value of 
sales made, as well as ABC analysis of sales (investigating the proportion of revenue 
generated by different products) 
 A policy of selling through the newly established People’s Pharmacies (PPs) increased 
the number of outlets of the RDF, as did the expansion to a number of national hospitals 
 The RDF took responsibility for transporting the drugs which are provided without charge 
for the first 24 hours of emergency treatment in public hospitals (drugs which are funded 
jointly by the FMoH and KMoH) 
 
Studies (Fundafunda, Bonface, 1998) noted an increase in utilisation of health facilities 
during this period, attributed to the RDF and also to the new health insurance system, which 
was introduced in 1997. 
 
In 2002, the Wali of Khartoum State signed a constitutional decree on the establishment of 
the RDF as an independent foundation, responsible for the medical supply in Khartoum 
State. An independent administrative board was established, chaired by the State Minister 
for Health. At the same time, 7 RDFs were set up in other states, financed by the Central 
Medical Supplies. 
 
The RDF now supplies113 health centres, 20 hospitals, and 22 community pharmacies. To 
run these it has a staff of 495. It has been operating successfully for 18 years and has an 
annual turnover of around £2 million. In 2003, it dispensed drugs to 1.2 million patients. As 
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one of the largest programmes of its kind in the world, there has been considerable interest 
in how the RDF has operated and an interest in expanding its work.  
 
 
 
Rationale for this study 
 
Evaluations in 1996 and 1998 concluded that the RDF has largely been a success story to 
date. One of the main concerns about revolving drug funds in general is that they commonly 
decapitalise, through failure to set adequate prices, or as a result of devaluation, or through 
management failures, pilfering etc. This has not happened with the Khartoum RDF.  
 
Another constraint in the early days was access to hard currency to import drugs from 
abroad. This was initially managed by SC providing a currency swap facility. Since the late 
1990s, however, the RDF has been assisted by the increased availability of hard currency in 
Sudan from oil revenues. This major concern, which appeared to threaten the project’s 
sustainability, has therefore been overcome. 
 
Concerns about political interference, which might threaten the survival of the RDF (by 
diverting funds from it) or undermine its independence as an operational unit, have also not 
been substantiated to date.  
 
There have however been some less successful aspects to the RDF. One of the areas of 
persistent weakness, commented on in earlier evaluations (AwadElKarim, Professor M. A., 
1996) (Fundafunda, Bonface, 1998), was the lack of community participation in the 
management of the RDF. 
 
Another issue which has been highlighted is that the RDF has no provision for those who are 
unable to afford its drugs (Fundafunda, Bonface, 1998). 
 
There were a number of reasons why this follow-up evaluation was commissioned by the 
KMoH, Save the Children UK and partners. 
 
One was to analyse how the RDF has changed since it was given independent status, and 
whether it is still fulfilling its mandate to provide access to quality, low cost essential drugs. 
 
Another was to draw lessons from the RDF experience which could inform the national roll-
out which is now taking place (with RDFs being set up in many of the other states of Sudan). 
 
Finally, while many of the previous studies had looked at overall functioning, none had 
focussed in depth on the issue of equity and of ascertaining who was benefiting from the 
RDF (and which groups were not able to utilise it). This was to be a focus for this study. 
 
 
Aims of the evaluation 
 
The evaluation team was asked to evaluate the functioning of the RDF since it became an 
independent body, focussing on the following questions: 
 
1. Does the Khartoum RDF ensure an adequate supply of quality, safe and effective drugs 
at below prevailing market prices? 
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2. To what extent is the population excluded to access to RDF drugs due to financial 
constraints?  
 
3. What models (subsidies/exemptions) can be used to provide a ‘safety-net’ for the most 
vulnerable? What will be the cost vs. coverage implications of these models? 
 
Structure of the report 
 
Chapter two outlines the research methods which were used in the evaluation. 
 
Chapter three examines the financial sustainability of the RDF, looking at recent trends, risks 
and liabilities. 
 
Chapter four examines whether the RDF is continuing to provide safe and appropriate drugs 
at below market prices. 
 
Chapter five examines issues of access – who is using the RDF and who is being excluded. 
 
Chapter six discusses the overall findings and their implications for the RDF’s role in future, 
as well as roll-out in other states. 
 
Chapter seven contains conclusions and recommendations.
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2. Research methods 
 
Overview of different components 
 
The study was designed and approved by a steering committee, which included 
representatives of the Federal Ministry of Health (FMoH), the KMoH, the RDF, WHO, 
UNICEF and Save the Children UK. 
 
Ethical approval for the research design, tools and sites was obtained from the KMOH and 
the Humanitarian Aid Commission, whose members were present during both the HEA and 
household survey field work. 
 
There were nine different components to this study: 
 literature review, to examine the RDF’s history and also to fit the study  findings into the 
context of wider developments in Sudan and internationally 
 interviews with key informants in Khartoum, to assess the policy context and to pick up 
concerns and suggestions for potential improvements to the RDF 
 household economy approach (HEA) study of different areas within the State, focussing 
on household livelihoods and coping strategies, and hence ability to afford health care 
and other basic goods 
 household survey focussing on health seeking behaviour, expenditure on health care, 
coping strategies, and perceptions of health facilities and the RDF  
 focus group discussions (FGD), which looked at the same questions as the household 
survey, but using qualitative techniques 
 health facility survey, which looked at prescribing practices, financial management and 
pricing structures, and some indicators of quality of care within RDF outlets 
 financial analysis of the RDF, to focus on profitability, operating costs, financial 
management and probity 
 pharmaceutical study, to look at issues of quality, pricing, procurement, management and 
the range of drugs which the RDF currently supplies 
 management study, focussing on the structure of the RDF, its human resource policies, 
management issues and legal status 
 
The literature review focussed on three areas: previous studies or written accounts of the 
RDF; any literature on health financing in Sudan; and international literature on the 
experience of operating drug revolving funds and related approaches, such as the Bamako 
Initiative. 
 
The key informant (KI) interviews focussed on collecting information from policy-makers in 
Khartoum, both within official and donor institutions. The management study was also based 
on KI interviews and review of documents, within the RDF and the FMoH and KMoH. A list of 
KI is contained in annexe 2.  
 
The remaining seven components are described in more detail below. 
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HEA 
 
The HEA component investigated different wealth groups, their coping strategies, and 
expenditures, in order to determine vulnerability in Khartoum State, and more especially to 
highlight any problems with ability to pay for health care. 
 
A group of 29 individuals from partner agencies and others participated in a 6-day training 
event incorporating both theory and practical aspects of household economy analysis.  One 
of the days was spent in the field.  Of these trainees, 18 were selected for the study, and 
allocated to one of 3 field teams.  Each team was balanced according to gender and ethnic 
group (ensuring particularly inclusion of both southerners and northerners in every team) and 
where relevant, staffed with specialists (e.g. agricultural specialists in the rural areas).  Each 
team was led by a household economy expert during the field work and analysis 
 
Livelihoods in Khartoum State are diverse – with three broad categories.  These include IDP 
households (living in IDP settlements or scattered within urban communities), “urban” 
residents and “rural” communities.   As precise population figures were not available for the 
disaggregated livelihood groups, the team made estimates as follows:  IDP: 20%; urban: 
70% and rural: 10% of Khartoum State population.  The study focused on the urban and IDP 
populations but two rural communities were visited to get an overview of livelihoods in rural 
areas. 
 
The next stage was to disaggregate each livelihood group into different wealth groups. The 
study used Household Economy Analysis (HEA) methodology to analyse household 
expenditure and income using a mixture of quantitative and qualitative techniques3.   
 
The urban community was sub-divided into three classes of suburb: Grade 1 (top), Grade 2 
(middle) and Grade 3 (poorest areas)4.  The HEA assessment covered communities in the 
Grade 2 and Grade 3 areas only.  A total of 6 communities were visited.  Selection was 
based on the urban grading system mentioned above and ensured selection of sites from the 
three major urban centres.  Communities visited included:  
 Khartoum: Burri, Idd Hussein 
 Omdurman: Kerari Jerafa, Shigla 
 Khartoum North: Thaiba El Ahamida, El Shabia  
 
Sampling of IDP camp populations was based on several other factors: (a) the status of the 
“planning” process in these areas5; (b) distance from labour opportunities; (c) coverage of the 
three major urban centres.  The team visited nine settlements where IDPs were living:  
Khartoum: Mayo Village, Mayo Farms (Mandela), Es Salaam (Jebel Aulia);  
Omdurman: Es Salaam (Jabarona); Wad El Bashir; Hara 42; Fatah 
Khartoum North: Hai Baraka; Idd Babikir. 
                                               
3
 For details about the methodology, see Save the Children (2000), Household Economy Analysis: a 
resource manual for practitioners 
4
 These categories relate to urban restrictions on building regulations in each area.  Those in the top 
area have to be built out of durable, expensive materials, are often multiple stories high and are 
situated in large plots. Poorer households living in these areas who inherited their property but who 
are unable to afford to upgrade their house to sufficient standard are likely to sell up and move out to 
grade 2 or grade 3 areas.  Grade 3 areas usually have only single-story houses made of mud. 
5
 This enabled us to ensure balanced representation of sites which had completed the planning 
process, sites which were in the middle of the process, and sites where the planning process had not 
started 
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The rural study visited two areas only6.  The field work for the rural areas lasted only 2 days 
and the information gained provided only a general overview.  Sampled sites were:  
 Omdurman: Salamaniya  
 Khartoum North: Sagai.   
 
 
A break-down of interviews conducted is given in table 1.  
 
Table 1 Breakdown of HEA interviews 
Household and type of interview Urban IDP Rural 
“poor” – complete household interviews 11 23 2 
“poor” – information only on incomes 3 3 0 
“middle” – complete household interviews 17 15 3 
“middle” – information only on incomes 5 1 0 
Total 36 42 5 
 
In this report, we summarise the HEA findings as they relate to the functioning of the RDF. 
For more detail on the wider results of the HEA study, see (Adams, L. & et al., 2004).  
 
Household survey 
 
The aim of the household survey was to gather quantitative data on health seeking 
behaviour, health expenditure and coping strategies by different populations within Khartoum 
State. This would provide evidence on the affordability of drugs and the extent to which 
people were unable to access RDF facilities. At the same time, the survey fills a wider 
information gap on household health care expenditure in Sudan. A more detailed report of its 
findings will therefore be published separately from this evaluation (Witter, S. & Babiker, M., 
2005). 
 
The household survey was prepared in June-July 2004 by the team of international and local 
consultants (see annexe 1). A three-day training workshop was conducted in Khartoum in 
July for the 10 field interviewers (predominantly, but not exclusively, female) and two 
supervisors. A day of field testing was carried out, followed by revision of the survey form. 
The fieldwork took 10 days, in late July/early August.  
 
The aim was to sample 500 households, from richer, middle class and poorer urban areas, 
as well as areas with higher proportions of internally displaced persons (IDPs). The 
classification of areas was carried out by the HEA team (see above). Table 2 gives a 
breakdown of the sampling locations.  
 
Table 2: Distribution of household survey sampling locations, according to area and residential 
class 
Location Type Khartoum Khartoum North  Omdurman All areas 
                                               
6
 Earlier discussions with key informants revealed that “rural” households constituted a small minority 
of the population and that most households engaged in peri-urban agriculture are relatively 
prosperous as they benefit from relative proximity to strong markets as well as the benefit of own 
production.   
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Urban high 
income 
1 - 1 2 
Urban middle 
income  
1 1 - 2 
Urban poor 1 2 3 6 
Rural  2 2 2 6 
Internally 
displaced 
2 3 2 7 
Total  7 8 8 23 
 
Within each location, households were selected by systematic random sampling techniques. 
A street is selected at random and then a house is randomly selected as well; the houses are 
then selected at systematic intervals (e.g. every tenth house is selected). If the house 
contains more than one household, the interviewers were instructed to choose only one 
household from that house. If a household refuses to be interviewed, the neighboring 
household is chosen instead. In fact, only one household (in Mandela IDP camp) refused to 
cooperate, so the response rate was close to 100%. 
 
After data cleaning, 700 household surveys were entered. The total number of individuals 
was 5,111. Of these, 52% were female and 48% male. 38% were under 15 years of age; 
58% were 15-60; and 4% over 60.  Their characteristics were found to be compatible with 
earlier demographic studies. 
 
Facility survey 
 
The main objective of this component was to triangulate the results of the pharmacy report 
and the household survey to assess costs, access and protection mechanisms. A second 
objective was to assess the quality of services being provided within RDF outlets, in order to 
understand whether the quality objectives of the original RDF programme were still being 
met.  
 
Following a review of current literature and WHO protocols, a questionnaire was developed 
that aimed to investigate the following main themes:   
 Staffing and personnel 
 Facility infrastructure 
 Functionality of key healthcare provision areas 
 Pharmacy management 
 Financial management - fees-for-service and drug fees 
 Use of exemption and insurance schemes 
 
The questionnaire was tested in four facilities - two health centres and two hospitals, not in 
the selected study sample - by the team of data collectors and adjustments made 
accordingly.  The final version was approved by the State Ministry of Health.   
 
Data collectors were selected from students undertaking post-graduate training in 
Community Medicine.  Potential clients were interviewed and their language and numeracy 
skills verified. 
 
Four data collectors were selected: three female and one male. They completed a two-day 
training workshop, followed by one day pre-test and then a further day to adjust the 
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questionnaire.  Only after the initial two-day workshop were the two teams identified, 
ensuring a balance in skills and confidence between the two teams.     
 
It was decided to undertake a proportionate stratified random sample of 25% of the health 
centres to ensure appropriate coverage across Khartoum State.  As the RDF groups the 
health centres into four locations for the purpose of supervision and monitoring, the health 
centre sample was stratified by location according the number of facilities in a location as a 
proportion of total RDF health centres.  From that point, health facilities were randomly 
selected. 
 
Given the much smaller numbers of hospitals using the RDF, it was decided to select a third 
of the total number of hospitals and stratify according to both location and geographical 
characteristic to ensure both urban and rural hospitals were selected. From that point, health 
facilities were randomly selected. 
 
People’s Pharmacies, which currently operate only in urban areas, were stratified by location 
and then randomly selected. Given that the information to be gained from the People’s 
Pharmacies would be limited to pharmacy management and infrastructure, 25% of the total 
number of People’s pharmacies was selected. 
 
Table 3 Health centres sampled in facility survey, by location 
 
Location Total no 
RDF 
health 
centres 
1:4 of 
health 
facilities  
Study 
sample 
Proportion of 
total RDF 
health centres 
in location 
Proportion of total 
RDF health 
centres  
East Nile  19 4.75 5 26.3% 4.95% 
Khartoum  34 8.5 9 26.5% 8.91% 
Khartoum 
Bahry 
23 
5.75 
6 
26.1% 
5.94% 
Omdurman  25 6.25 6 24.0% 5.94% 
Total 101 25.25 26  25.74% 
 
Table 4 Hospitals sampled in health facility survey 
Location Total no RDF 
hospitals 
1:3 of  RDF 
hospitals  
Study 
sample* 
Proportion of 
total RDF 
hospitals  in 
location 
Proportion 
of total 
RDF 
hospitals  
East Nile   
 
 
 
 
Khartoum  7 
2 
2 
28.6% 
10.5% 
Khartoum 
Bahry 
6 
2 
2 
33.3% 
10.5% 
Omdurman  6 
2 
2 
33.3% 
10.5% 
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Total 19 6 6 31.7% 31.6% 
 
Table 5 People's Pharmacies sampled in health facility survey 
Location Total no 
RDF PPs 
1:4 of  RDF 
PPs  
Study 
sample  
Proportion of 
total RDF  PPs 
in location 
Proportion of 
total RDF 
PPs  
East Nile   
 
 
 
 
Khartoum  6 
1.5 
2 
33.3% 
11.8% 
Khartoum 
Bahry 
5 
1.3 
1 
20.0% 
5.9% 
Omdurman  6 
1.5 
2 
33.3% 
11.8% 
Total 17 4.3 5 28.9% 29.5% 
 
Data was entered into SPSS (version 10.0.5).  Analysis was done using Excel 2002.  
 
A full report on the health facility survey is published separately (Cadge, N. & Elkarim, 
Professor M., 2005). 
 
Focus group discussions 
 
The aim of the FGDs was to add qualitative information to the data gained from the 
household survey on health care choices and perceptions, including of the RDF. 
 
Two teams of data collectors (each with one man and one woman) were trained in PRA 
techniques. 
 
Discussions took place with 20 groups, split into males and females, children and the elderly. 
Groups ranged in size from 5 to 10 participants. A total of 140 people participated. 21 key 
informants were also interviewed. The research was carried out in 12 areas of Khartoum 
State. The areas were selected to include a variety of settings, including IDP camps, rural 
areas, semi-urban and urban sites. 
 
Different tools were used, including preference ranking, matrix scoring, mapping, modelling, 
and seasonal and historical diagrams. 
 
 
Financial analysis 
 
The financial study aimed to establish the current financial viability of the RDF, its financial 
management and options for improving profits or reducing costs. This component was 
outsourced, using Save the Children UK’s standard tendering procedures. The following 
activities were carried out: 
 
 a financial evaluation of the financial statements of the RDF for a period of three years 
 a review of the cash collections vis-à-vis invoices  
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 an assessment of the running costs of the project 
 evaluation of income in the financial statements (both cash and in-kind) 
 review of effects, if any, of inflation, stock losses and currency fluctuations on the project 
management and sustainability 
 analysis of capital investment plans 
 
These were examined by a review of internal RDF documents and discussions with RDF 
staff members. 
 
Pharmaceutical study 
 
The objectives of this component were: 
 To asses the compliance of the RDF drug list with WHO policy and the National Drug 
Policy 
 To evaluate the mechanisms for procurement, quality control, warehousing and stock 
control 
 To conduct a market survey in order to compare RDF prices with other drug suppliers 
 
The methods used for this component included structured interviews, observation, secondary 
data and a market survey. 
 
Interviews were conducted to obtain information from RDF key informants regarding logistics 
concerning drug supply, provision of other services such as supply of equipment and 
instruments to hospitals, and research. Topics included the supply of rural health facilities 
with essential drugs, the competitiveness of RDF prices, the impact of RDF drug supply on 
primary health care coverage and rational use of drugs, funding of research and the 
successes and failures of the RDF. 
 
Literature provided by the RDF in the form of annual reports, guidelines and stock ordering 
forms were consulted. WHO and Federal Ministry of Health guidelines and drug policies were 
also reviewed. 
 
For the market survey, 17 pharmacies were randomly selected - 12 of them were private 
pharmacies (out of a total of 565 in Khartoum State) and 5 were popular pharmacies (out of a 
total of 77).  
 
After validity and consistency were checked and the data cleaned, the data was analysed 
using SPSS.  
 
Study constraints and limitations 
 
One constraint noted by researchers was that the overall study was ambitious in scope, with 
many different components, which resulted in a split into different teams, and a challenge to 
integrate all of the findings.  
 
The timing of the study was also not ideal. The original aim had been to influence the design 
of roll out of RDFs in other states in Sudan, but logistical and funding issues meant that the 
process was delayed, so that the recommendations are likely to have less impact at this 
stage, with roll-out already underway. Both the funding agencies and many other 
stakeholders have also been understandably preoccupied by the peace settlement in the 
South and the problems faced in Darfur.  
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Despite these two overall constraints, the findings of these studies are very timely given the 
discussion of health sector strategies post-peace agreement and the potential changes to the 
situation of IDPs in Khartoum.  
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EVALUATION FINDINGS 
 
3. Financial sustainability of the RDF 
 
This section will look at the overall financial health of the RDF, which includes the following 
issues: 
 The RDF’s different revenue streams and their profitability 
 Overheads and cost controls 
 Measuring efficiency 
 Use of RDF surplus 
 Capital expenditure and investments 
 Financial reporting 
 Risks and liabilities 
 
Pricing and profitability 
 
The RDF operates in a number of different markets. It supplies emergency drugs to hospitals 
for free (the KMoH and FMoH pay for the drugs, which the RDF distributes without charging 
for the service). It supplies a high volume of locally manufactured drugs to the People’s 
Pharmacies7, with a fixed mark-up of 20% (which is set by the Federal Department of 
Pharmacy). For the imported drugs which it supplies to health centres, hospitals and 
People’s Pharmacies, it can set its own mark-up, which has varied over time. (The mark-up 
on imported drugs sold to People’s Pharmacies is 10% lower than that used for RDF 
facilities, to reflect the fact that People’s Pharmacies add their own additional mark-up of 
20%). 
 
In 1991, the mark-up for RDF facilities was 13%. However, by 2000 it had risen to 64% 
(Gamaleldin Khalafalla Mohamed Ali, 2000). This figure broke down into: 
 15% for operating costs 
 10% for recapitalisation (after the devaluation of the Sudanese Dinar (SDD) in the 990s) 
 5% for drug losses 
 4% for international drug price increases 
 30% to cover local inflation 
In 2002, this was reduced to 58%, and in 2003 it was set at 51%.  
 
In terms of the locally manufactured drugs, the RDF has no particular price advantage. 
However, for the imported drugs it enjoys the advantage of its import tax-free status (worth 
                                               
7
 People's Pharmacies are quasi-public establishments retailing drugs and medical supplies at below 
market prices to improve access and availability of pharmaceuticals. They were founded in the early 
1980s as a pilot study for a drug cost recovery system. They differ from the private commercial 
pharmacies, firstly, in having access to the CMSPO drugs - i.e. generic and large pack products - in 
addition to the brand products from the private wholesalers. Secondly, the People’s Pharmacies are 
owned by public organisations (e.g. hospitals), people's committees, trade unions and NGOs. Their 
mark-up on cost for drugs from the CMSPO was 35%, from the RDF (imported drugs) about 20% and 
from private drug wholesalers, 10%. However, they have become commercialised now and operate in 
a similar way to private pharmacies. 
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17.5% of the value of the imported drugs), which is not shared by other importers, notably 
the CMSPO8. 
 
In the health centres and hospitals, the RDF is selling direct to the patients – in other words, 
the risk of losses, expiry of stocks etc is borne directly by the RDF. For some other clients, 
such as People’s Pharmacies and NGOs, the RDF sells the drugs to the institution and 
thereafter, any issues of cost recovery are a problem for the institution, not the RDF. This is 
an important distinction. In the case of the other state RDFs, the model has been adapted, so 
that each level sells on to the one below, rather than taking responsibility for the full cycle of 
sales to the client. The risk of shortfalls is therefore passed down the line. 
 
Table 6 shows the balance of revenue and profit coming from drugs sales through the 
hospitals and health centres (the RDF account) and the People’s Pharmacies. The People’s 
Pharmacies provide the bulk of the revenue (57%, rising to 60% in 2003), but because of a 
smaller mark-up on the locally purchased drugs, its contribution is smaller than the RDF 
stream (40%, rising to 43% in 2003). Nevertheless, this side of the business is growing, and 
once distribution costs are taken into account, the difference may be small. 
 
Table 6 RDF revenues and gross profit from two streams, 2002-3 
  2002 2003 
 Amount in 
GB£9 
% of the 
Total 
Amount in 
GB£ 
% of the 
Total 
Revenues RDF 2,698,335 43% 2,541,902 40% 
PPs 3,521,658 57% 3,879,128 60% 
Total 6,219,993  6,421,030  
      
Gross margin RDF 886,791 60% 861,283 57% 
PPs 587,675 40% 646,521 43% 
Total 1,474,466  1,507,804  
 
 
One measure of overall profitability is the gross profit ratio. This is derived by comparing the 
gross profit with the sales.  In 1999 the rate was 15.25%, and by end of 2003 it was 21.97%.  
In fact, since 2002 when RDF became an independent government entity, the gross profit 
ratio has been increasing, and is expected to do so in 2004. There is no fixed ‘ideal’ gross 
profit ratio, but given the RDF’s objective of providing affordable, quality drugs, there is a 
strong argument to be made that the gross profit should not increase much beyond around 
15% (which still leaves sufficient surplus for reinvestment in business development). 
 
The net profit ratio looks at the overall profitability from a trading venture/project.  This ratio is 
between the net reported profit and sales.  In 1999, the ratio was 1.36%, increasing to 3.16% 
in 2000, but then dropping back to 1.56% in 2001.  In 2003, the ratio was 9.92% (the net 
profit before the subsidy paid to KMoH of SDD 164.9 million).  
 
The value of drugs sold has been increasing, year on year, but with a particularly large rise 
between 2001 and 2003 (see table 7): 
                                               
8
 Note though that both the CMSPO and the RDF enjoy tax privileges relative to the People’s 
Pharmacies and private pharmacies, which pay 32% of net profits in tax. 
9
  1GBP= 410 SDD in 2002 and 450 in 2003. 
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Table 7 Value of drugs sold by RDF, 1999-2003 
Year Increase in value of drugs sales 
(%, compared with previous year) 
1999 17.22% 
2000 21.02% 
2001 39.28% 
2003 143.16% (NB. For a two year period) 
 
This increase in profit is largely attributed to the growth in sales to non-RDF institutions (i.e. 
People’s Pharmacies).  
 
Overheads 
 
In the early days of the RDF, operating costs were low (1-4% of total revenue), partly 
because Save the Children UK was still supporting many of the recurrent operating costs. 
From 1996-2000, expenditure increased to between 8 and 12% of revenue (Gamaleldin 
Khalafalla Mohamed Ali, 2000). 
 
There is some concern now that overheads have continued to increase, particularly staff pay 
and incentives. As of 2003, the RDF has had to pay its staff salaries, which were previously 
paid by the KMoH (though the RDF used to pay incentives to the KMoH staff). This is part of 
the switch to independent status. However, the rise in costs is also attributed to salary 
increases and rising allowances. For example, the salary of a driver has been raised five 
times in the past two years and those of other staff more than doubled, and are well above 
current MoH levels. Whether this is justified is doubtful, given that the exchange rate has 
been fairly stable and inflation under control over this period. 
 
Figures for operating and administrative expenditure are given in table 8. 
 
Table 8 RDF operating costs, 1999-2004 
Year Operating and admin costs (SDD 
thousands) 
1999 51,767 
2000 71,974 
2001 92,241 
2003 308,845 
2004 506,787 
 
  
The huge increase in 2003 as compared with 2001 is for a two year period and covers a 
period when the RDF business was still expanding.  Even so, the increase is high, and 
remains high for 2004.  Wages, salaries and incentives rose from SDD 64.9 million in 2001 to 
SDD 180.1 million in 2003 and SDD 259 million in 2004.  The increase over three years is, 
therefore, nearly four-fold.  In 2004, salaries and allowances constituted 51% of operating 
costs. 
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Incentives increased by 66% between 1999 and 2000, and by nearly 100% between 2000 
and 2001.  Incentives paid during 2003 also amounted to a significant amount. 
 
As of April 2004, a government minimum wage of 12,500 SDD came into force, but this 
cannot account for increases in staff costs during the earlier period. A system of paying 
incentives for increased sales for all of those in the supply chain was also introduced recently 
and this will contribute higher sales and also higher expenditure on pay and incentives. It is 
important that financial incentives do not work against the drive for rational prescribing (see 
later). 
 
Incentives should be performance-related, but should also be capped at a proportion of 
salary (e.g. 50%), to stop them from spiralling out of control or being abused. 
 
Another significant expenditure item in 2003 was training (SDD 9.2 million).  This training 
may well have been necessary to prepare staff for the changes in the RDF moving from 
project to independent government entity. 
 
Surprisingly, transport and fuel costs have not increased significantly over the last four years.  
For instance, they increased by only 10% between 1999 and 2000; and decreased by 30% 
between 2000 and 2001.  In 2003, these amounted to SDD 8.3 million only.   
 
Good stock control is essential to keep adequate quantities (not excessive, but not so low as 
to run out of essential drugs) and reducing losses. The change in stock inventory system and 
employment contract was credited with bringing the RDF from a loss- to a profit-making body 
after hand-over in 1996. 
 
The rates of wastage were recorded as virtually nil in 2000, thanks to efficient stock control 
procedures (based on consumption information, and using a ‘first in, first out’ approach), as 
well as anti-theft measures (Gamaleldin Khalafalla Mohamed Ali, 2000). In recent years, 
however, expired drugs written off have been rising.  In 2003, they amounted to SDD 3.08 
million, compared to SDD 0.7 million in 2001. According to the 2004 annual report, the RDF 
facilities lost 2.2% of their stock through expiry, while the PPs lost only 0.5%. Although this 
remains a small proportion of stock values, this trend is of concern. 
 
In the facility survey, 31% of health centres, 40% of People’s Pharmacies and 1 out of 6 of 
the hospitals reported having expired drugs in stock, varying from 1-3 items.  A similar 
proportion reported having stock that would expire within the two months. This suggests that 
the RDF systems for reducing stock losses may need tightening up. The management plans 
to introduce a new system for checking pharmacy records against RDF ones, to reduce stock 
losses. This is an urgent issue to pursue.  
 
The management accounts of RDF provide the necessary cash reconciliation vis-à-vis 
theoretical cash which should have been collected from the sales.  Given that the differences 
are small, less than 1% in most cases, we conclude that there is effective control over cash 
collections. 
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Measuring efficiency 
 
One measure of efficiency is the working capital efficiency ratio. This relates to the stock 
turnover.  It is calculated either as stock turnover per year or as the number of days that it 
takes for stocks to turnover on average. 
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Table 9 Working capital efficiency measures, 2000-3 
Year No. of turnovers per year No. of days to turnover Working capital 
cycle 
1999   24.5 days 
2000 5.19 times 70.3 days 26.5 days 
2001 5.73 times 63.66 days 44.9 days 
2003 2.55 times 142.98 days 86.3 days 
 
Table 9 shows that stocks have been building up since 2001 and that the working capital 
cycle has nearly doubled over 2001-3. The dangers in the stock build-up include the potential 
for: 
 
 higher losses due to spillage and poor warehousing conditions; 
 increase in losses due to expiry dates for slower moving drugs; 
 increase in stocking costs – warehouse space, air conditioning, etc; 
 loss in value of drugs which are superseded by other cheaper drugs. 
 
The management should decide on an optimum stock holding - taking into account expected 
sales patterns, and the time span required between placing an order and receiving supplies 
in the warehouses - and work to eliminate excess stocks, based on that level. 
 
Use of RDF surplus 
 
The initial agreement between Save the Children UK and the KMoH stated that 6% of the 
RDF sales should be transferred to the KMoH to finance other PHC investments. This is 
viewed partly as payment for the benefits which the RDF gets from operating through public 
facilities, such as the hospitals and health centres, which the KMoH has to maintain. 
 
This transfer is now 17.5 million SDD each month (3% of People’s Pharmacies sales and 
13% of RDF sales), which equalled 7% of overall sales in 2003. The proportion of RDF sales 
revenue that is being transferred has more than doubled since 1995, and the amount of 
money received by the KMoH has also doubled, in the light of the growth in RDF business 
and the addition of the People’s Pharmacy income stream (which did not exist when the 
original agreement was drawn up). Some concerns have been expressed that the current 
level is eroding the RDF surpluses and thus undermining its ability to keep up with payment 
to creditors (see below) and to invest in its own business and so ensure future sustainability. 
 
How it is used is not entirely clear, but some portion at least was used to pay off the debts of 
the Cardiac Centre, which raises questions about appropriateness as well, as the original 
aim was for the RDF to support improvements in the quality of PHC. It is hard to track this 
area, as money is fungible, but there is a risk that the RDF transfers are not adding to PHC 
budgets, but are substituting for other funds. 
 
Capital expenditure and investments  
 
In the past, capital items were not reflected in the RDF accounts, as their costs were 
absorbed by the funding agency. The RDF must now reflect full costs of capital items, 
including depreciation and maintenance (even if items have been donated). 
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In 2004, the management drew up plans in place to move to its own offices and to procure 
new fixed assets worth more than US $30,000.  A new warehouse was also built in 2004. It is 
not clear whether a cost-benefit analysis was carried out between investing in premises and 
using the cash alternatively on providing additional drugs to the needy.  While it is recognised 
that new premises enhance the image of the RDF as a business, the management should 
have prepared capital investment plans at least 3 years in advance and had them authorized 
by the board and stake-holders. 
 
The RDF has invested in the Khartoum Medical Insurance Services Company (a public share 
company). The KMISC is a subsidiary of the KHIC, which owes money to the RDF and 
whose business is closely linked to the RDF. This raises concerns about risk-spreading: if 
the KHIC were to collapse, the RDF would be multiply affected, through the loss of its largest 
purchaser, the likely non-repayment of debts and the loss of value of its shares in the KMISC 
company (it owns 40% of the shares). The short-fall in revenue for 2005, related in part to the 
dispute between the KHIC and the FHIC, illustrates this vulnerability. 
 
Internal financial controls and reporting 
 
The financial review indicates that the project has continued with more or less the same 
internal control systems that were in use prior to it becoming an independent government 
entity.  It finds that there is good internal control system. The project has also adequate 
financial procedures manuals (which were updated for its ISO application, now successfully 
completed).  The manuals are appropriate to the circumstances. A number of detailed 
recommendations for improving systems are outlined below. 
 
1. As regards the design of payment vouchers, these should be modified to include details on 
budget availability for an expenditure line item (or, if there is no budget for a proposed 
expenditure, with a full justification attached). 
 
2. Fixed assets were introduced in the financial statements from 2002.  Prior to that there 
was no accounting of these assets (whether donated or purchased).  Like other types of 
assets, fixed assets must also be controlled.  One way of controlling fixed assets would be 
introduce a fixed asset register.  Such a register would provide detailed information regarding 
purchase, depreciation status, insurance coverage, condition of each item and location. 
 
The management should either introduce a manual of fixed assets or purchase a fixed 
assets software module as part of an overall computerized accounting package. 
   
A full inventory of all fixed assets should be carried out. All those not already reflected in the 
accounts since 2002 (meaning either purchased in the past or donated to the project) should 
be revalued independently and reflected in the accounts by way of assets revaluation. All 
fixed assets should also be depreciated. 
 
3. The project accounting records are kept partly manual and partly computerized.  The 
accounts are periodically closed off.  The closing off depends on returns from various health 
facilities to which RDF provides drugs.  In most cases, the health facilities provide reports in 
time to the head office.  Obviously, in running such a large number of facilities, delays are 
bound to occur, and they should be accepted given that most facilities rely heavily on their 
accountants to prepare the reports (including stock taking reports verification).   
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The project is expanding rapidly as the demand for cheaper drugs continues to rise.  Most, if 
not all, facilities continue to rely on manual accounting records.  This could be cumbersome 
and delays could occur in recording transactions on a daily basis and then reconciling them 
with inventories.  Also at the head office level, there is a need to computerize the entire 
accounting, payroll, and assets control functions.   
 
Therefore, it is recommended that a separate review should be carried out to see which 
functions could be computerized and at which locations. 
 
4. As a result of incorrect accounting in 2003, custom clearance of vehicles was treated as 
running costs rather than being capitalized.  Customs clearance and car insurance amounted 
to SDD 14.3 million. This should be corrected. 
 
5. The annual and periodical management reports include considerable information. 
However, some improvements could be made, such as: 
 including clear definitions (e.g. on the distinction between administrative and operating 
costs) 
 making annual comparisons between budgeted and actual expenditure 
 including cash flow analysis  
 providing additional information, for example on the basis for calculating the subsidy to 
the KMoH 
 
 
Liabilities and risks 
 
Liquidity 
 
The current ratio compares the current assets of the RDF with its liabilities.  The idea is to 
ascertain whether the project has the ability to meet its short term obligations out of its short 
term assets.  In an ideal situation, the ratio would be 1:1, but in practice current assets 
should be slightly higher than the short term obligations, which is the case for the RDF (see 
table 10). 
 
Table 10 RDF assets: liabilities, 1991-2003 
YEAR Total Assets 
(£, 000s) 
Total Liabilities 
(£, 000s) 
1991 1,497 39 
1992 875 0 
1993 1,302 4 
1994 1,271 28 
1995  
1,098 
37 
1996 1,398 35 
1997 1,149 63 
1998 905 43 
1999 1,172 123 
2000 1,465 251 
2001 1,718 334 
2002 2,148 677 
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2003 2,070 690 
Source: (Gamalgeldin, K. M. & Fundafunda, B., 2004) 
 
Inventories, debtors and creditors were increasing over this period. For example, debtors 
increased by 28.98% between 1999 and 2000, by 26.06% between 2000 and 2001, and over 
a period of two years to 2003 by 62.55%. This is worrying, especially as some of the debtors 
were influential tertiary institutions, such as the Cardiac Centre.  
 
One of the main outstanding debts was from the KHIC, which rose from SDD 100 million in 
2001 to SDD 344.5 million in December 2003 – the rise in sales not being matched with a 
rise in collections. However, a recent Insurance Act which transferred the surpluses of the 
insurance companies to the government has galvanised the KHIC to repay debts – including 
to the RDF – in order to reduce its surplus and liabilities and this has reduced the 
outstanding debt from the KHIC.  
 
On the other hand, creditors increased by 62%, 10% and 324% in 1999-2000, 2000-2001 
and 2001-2003. These are mainly European drugs suppliers. 
 
Over the two year period to 2003, the increase in creditors outpaced that of debtors. By the 
end of 2004, funds owed by the RDF were 460million SDD more than those owing to it. If 
suppliers requested immediate settlement of their debts, the RDF would have a problem 
meeting its obligations. 
 
The creditworthiness of the RDF has been one of its main achievements, and also a source 
of competitive advantage, as it has been able to order drugs from abroad without having to 
pay upfront. In 2003 it imported $2.5million worth of drugs, compared to $500,000 purchased 
from the local market. This creditworthiness would be endangered if the RDF fell behind in 
payments. The RDF management is however now taking measures to pay off its creditors. 
 
 
Table 11 RDF debtors and creditors, 2000-3 
 
 2000 2001 2002 2003 
Debtors GB£, 000s GB£, 000s  GB£, 000s  GB£, 000s  
MoH 0 38 13 10 
Health Centres & hospitals 248 264 268 263 
People Pharmacy 91 32 116 1 
Health Insurance 31 68 61 49 
Epidemiology Department 0 90 2 21 
Hospital department 0 0 0 165 
Marwa Pharmaceutical 0 0 0 0 
Cardiac Surgery Centre 0 123 87 435 
Others 48 24 67 41 
     
Total 418 639 614 985 
Creditors     
MoH 105 0 28 21 
Lab. Account 0 8 0 0 
Drug Companies 26 327 503 541 
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Cardiac Surgery Centre 3 0 0 0 
CMSPO 29 37 48 39 
Animal Resources Bank 13 14 12 11 
People Pharmacies 65 0 39 0 
FMoH 0 18 0 0 
Others 9 113 47 77 
     
Total 250 517 677 689 
 
It is clear from table 11 that debtors and creditors have been increasing over time, and that it 
is largely the non-paying hospitals which are causing liquidity problems, and which threaten 
the RDF payments to drug companies. If allowed to continue or re-occur, this would damage 
the RDF’s reputation and undermine its terms of trade. 
 
Foreign exchange availability 
 
When the project originally started in 1980s, there was a drastic shortage of foreign currency 
in the country.  Further, due to various economic problems, the value of the local currency 
devalued continuously up to 1996, leading to an annual inflation rate of 161%. Since then the 
country’s economy has performed well.  In 2004 annual inflation was between 12 and 15%, 
and the rate of exchange stabilized between 1999 and 2003.  During 2004, the Sudanese 
Dinar rose against the dollar (against which it is pegged), and by January 2006 it was SDD 
233. 
 
Based on the above, the financial statements of RDF have shown only modest exchange 
rate differences.   
 
As regards the availability of foreign exchange, the banking system has a surplus and since 
medical imports are given a priority, the RDF should have no problem in obtaining its foreign 
currency imports at prevailing banking exchange rates. 
 
Other risks 
According to the RDF manager, the People’s Pharmacies now provide two-thirds of the RDF 
revenue. The financial viability of the RDF therefore depends on the continuation of this side 
of the business. If moves were made to separate the two businesses, that would have a 
serious impact on the viability of the supply of drugs via the RDF to health centres and 
hospitals. Similarly, the RDF has come to depend on its main purchaser, the Khartoum HIC, 
which provides 52% (753 million SDD) of the People’s Pharmacy sales and 43% (223 million 
SDD) from RDF hospitals and health centres sales (RDF annual report 2002). If the 
Khartoum HIC were to suffer a business set-back that would have serious consequences for 
the RDF. This is however judged to be unlikely, given the scale of the KHIC and the 
commitment to continuing with health insurance. 
 
There has been discontinuity of management over the past two years, in the RDF, with two 
directors resigning and an acting director appointed in the interim. The Board of Directors 
had also not met recently, at the time of main data collection in 2004. This is worrying given 
that the RDF requires active leadership and advocacy at the national level if it is to continue 
to enjoy political support and maintain its good record. However, it is hoped that the 
appointment of a permanent director in 2005 will settle these concerns. 
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Summary of financial findings 
 
The RDF has continued to grow, in terms of volume of sales and assets, and remains in 
good financial health, in terms of its assets to liabilities ratios. However, a number of trends 
should be noted. 
 
1. The increase in sales value, profit margins, capital investments and salary costs could 
indicate that the primary ethos of the RDF is changing to a more commercial one from its 
original public service purpose. 
 
2. Increases in stocks (inventories) and turnaround times for stock indicate a trend towards 
less efficient and careful management of resources, which should be curbed. 
 
3. Decreases in attendances at RDF facilities and problems with the health insurance system 
have resulted in reduced profits for the past three years. This is a worrying trend. 
 
4. Some important information is missing from recent accounts (e.g. accounting policies, 
sales volumes, budgets, value of gifts in kind), which should be remedied both for 
management and auditing purposes. 
 
5. Possible future risks to the financial viability of the RDF include defaulting by debtors; 
attempts to separate off the side of the business which supplies the People’s Pharmacies; 
excessive extraction of surpluses by the KMoH; political interference; and removal of the 
RDF’s tax privileges. Its relationship with the MoH is crucial to maintaining its independence. 
High level support, for example, from the Wali, has helped it to date. 
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4. Supply of quality, safe and effective drugs at below 
prevailing market prices 
 
The second important area for investigation in this study is the extent to which the RDF is still 
meeting its mandate to supply appropriate, safe and affordable drugs.  The main questions 
here include the following: 
 Is the RDF still focussing on essential drugs and on promoting rational prescribing? 
 Are RDF prices below prevailing market alternatives?  
 Are essential drugs fully available at all RDF outlets? 
 Are supervision and quality control systems operating effectively? 
 
Range and appropriateness 
 
At its inception, the RDF supplied mainly prescription essential drugs, but it has now 
expanded to include radiographic materials and surgical sundries. This reflects its increasing 
role as supplier to hospitals in the State, as well as its expanded sales through People’s 
Pharmacies. Recently, the standard list for health centres and hospitals was expanded to 
contain Sexually Transmitted Diseases and IMCI (Integrated Management of Children 
Illnesses) programme medicines. In 2000 it had 85 items on its main list and 109 additional 
items (Gamaleldin Khalafalla Mohamed Ali, 2000). By 2004, the main list had increased to 
145 items. This expansion of stock – noted in chapter 3 – brings with it increased financial 
risks, as well as increased sales opportunities. 
 
The Sudan National Essential Drug List (NEDL) consists of approximately 246 items, 
selected within the ramifications of both WHO policies and the National Drug Policy. The 
drug list of the RDF (145 items) covers a wide range of drugs from this NEDL. All of the 
drugs supplied to RDF facilities, apart from the multivitamins, are essential drugs and 
generics. The People’s Pharmacies list, however, contains more than 2,500 items, including 
essential and non-essential medicines, generic and brand products from different companies, 
and other disposables and cosmetics.  
 
A formal breakdown of People’s Pharmacies annual sales into essential and non-essential 
drugs is not available, but anecdotally, essential drugs constitute only 10-15% of the total. 
Almost all of the items sold through PPs are brand-name items, which are of course much 
more marketable than generics. Previous evaluations noted a growth in brand-name 
prescriptions (23% of sales in 1989-95; and 50% in 1996 (AwadElKarim, Professor M. A., 
1996). However, it is hard to make an accurate assessment as prescribers commonly write 
brand names on prescriptions, but patients are actually dispensed the generic drugs, which 
are in stock.  
 
A small group of 10-20% of the items, such as chloroquine, certain antibiotics, the penicillin 
group, disposable syringes, multivitamins and infusion solutions, usually account for 75-80% 
of the Fund expenditure.   
 
A fall in sales through RDF facilities in 2005 is attributed in part by the management to the 
fact that the NEDL is out of date, and does not match the drugs which are currently being 
prescribed.  The RDF has added some new drugs in 2005 in an ad hoc way, but there is a 
need for an updating and review of the NEDL, which is a federal responsibility. 
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Table 12: Rational drug indicators – trends in RDF facilities 
Indicator 1989-95 1996 2000 2004 
Optimal  
value 
Average number of medicines prescribed per 
patient encounter 1.7 1.8 2.1 1.9 < 2 
% of drugs using generic name   50% 41%   100% 
% of encounters  with an antibiotic prescribed     59% 71%  <30% 
% of encounters with an injection prescribed     29% 21% <20% 
% of encounters with an antimalarial prescribed     33% 20%   
% of medicines prescribed from essential 
medicines list or formulary   100% 99% 100% 100% 
% of key medicines available   100% 100% 97% 100% 
Availability of essential medicines list or 
formulary to practitioners       97% 100% 
(Source for optimal values: (Dumoulin, J. et al., 1998). 
 
Table 12 tracks some indicators of rational drug use (data is not available to follow all of the 
WHO indicators). The number of medicines prescribed per patient has risen slightly over the 
years, but remains within the optimal range. Generic drugs appear to be falling, but there is 
no data from 2004 to confirm this trend. The number of encounters including an injection is 
declining and are just above optimal levels, but antibiotics have increased from a level that 
was too high, to one that is more than double the desirable level. This points to the need for 
increased action by the RDF and KMoH to educate prescribers and the general public on the 
dangers of overuse of antibiotics and to actively promote rational prescribing. 
 
The proportion of ORS to the total number of drugs prescribed has decreased from an 
already low baseline in 1996.  The 2004 health facility survey showed that only two patients 
were prescribed ORS to take at home, which raises concern about diarrhoeal disease case 
management, particularly in the under-five age group.  
 
Another area of concern is the increased use in syrups/suspensions, which rose from 18% in 
1996 to 21% in 2004.  In Khartoum, temperatures generally exceed 30oC in the daytime (and 
in the hot season 40oC), very few households have access to refrigeration facilities and water 
quality is questionable in many areas for the safe reconstitution of the suspension.  The 
amount of water used for reconstitution directly affects the dose and needs to be accurately 
measured and mixed. In addition, syrups are usually more expensive than tablets and are 
bulky and heavy, and therefore costly to transport as well as difficult to store. 
 
In the prescription review, prescriptions from hospitals had a significantly lower number of 
drugs per patent than health centres and People’s Pharmacies.  There was no correlation 
between the number of drugs prescribed by location or rural area or whether the facility 
accepted patients using health insurance.  Analysis of the use of the various drug groups by 
facility type showed only a statistically significant difference between health centres and 
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People’s Pharmacies, and hospitals and People’s Pharmacies, with the prescriptions 
reviewed from the people’s pharmacies having significantly less antibiotics.  
 
The health facility survey was not able to look at the patients’ understanding and use of 
drugs. However, some insights come from the FGDs, which confirmed that families 
sometimes buy some but not all of the drugs or dose prescribed. Others reported self-
prescribing and borrowing drugs from neighbours. 
 
"It is normal to borrow drugs from my neighbour, because I may not have enough money to 
buy a drug or go to the health centre. If a neighbour had the same illness as that of mine I 
will not hesitate to take the same drug if she found it useful" (KI from IDP area) 
 
The participants expressed a preference for injections over tablets, especially for malaria, 
and for syrup over capsules for cough or ARI. Some also thought that more expensive drugs 
were likely to be more effective (though this view was not universally held). 
 
Although they felt that the explanation given by the pharmacist was usually clear, many 
reported not finishing the course of drugs when they felt better, though they claimed to be 
more careful with children’s illnesses. 
 
From these findings, we conclude that the range of RDF drugs is appropriate, but that more 
could be done to encourage rational prescribing and use, particularly in relation to reducing 
antibiotics and syrups, increasing use of ORS and improving patients’ understanding of the 
need to take drugs as prescribed and to finish the course. In order to change the prescribing 
behaviour of practitioners and strengthen the monitoring role of the pharmacists, continuous 
training and regular pharmacy updates are required.  This was a recommendation in both 
1996 and 2000 reports and yet indications are that the irrational use of drugs, particularly 
antibiotics, continues.  This issue needs to be addressed seriously by all stakeholders in 
healthcare if this situation is to be improved.  The RDF management also needs to ensure 
that its drive for profit (e.g. through incentives to pharmacists to increase sales) does not 
jeopardise the drive to improve prescribing practices. 
 
 
Price 
 
A major rationale for the RDF was to provide essential drugs at lower prices than were 
available from other outlets, and previous evaluations have found that RDF prices were 50-
60% cheaper than private pharmacies (Fundafunda, Bonface, 1998). This average masks 
differences within the list. There is cross-subsidy within the RDF supplies to health centres 
and hospitals, so that more expensive drugs are made more affordable. (Insulin, for example, 
has a mark-up of only 10 %.) 
 
This study investigated price differences between RDF and non-RDF sources through a 
market survey of a sample of different outlets, and through a prescriptions review in our 
health facility survey. 
 
The prices of 143 drugs sold by private pharmacies, People’s Pharmacies, the CMSPO and 
the RDF are listed in annexe 3. Comparison of prices is made across the 66 items which are 
common to all sources.  
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The results of the market survey show that private pharmacies are 1.2-6.5 times as 
expensive as the RDF, averaging twice as much across the list of 66 items. The People’s 
Pharmacies are also more expensive – 1.9 times as much on average, with a range of 1.3-
4.3. On the basis of these figures, it seems that the price differential with the private sector 
has remained at around the same level as in previous evaluations. 
 
With the CMSPO, the difference is smaller but still favours the RDF overall – its prices 
exceed the RDF’s by 40% on average. However, for a smaller selection of common drugs 
(see table 13), the comparison is in favour of the PMSC and ranges between a ratio of 0.3-
1.2 times the RDF prices (0.9 on average)10. This reflects the cross-subsidies operated by 
the RDF, which raises the price of cheaper, more common items relative to more expensive 
ones. It is debatable, from an equity point of view, whether this cross subsidy is optimal, and 
this issue should be revisited by the RDF management. The increased prices of some of the 
items may also be linked to the RDF’s decision to import items, for quality reasons, which 
competitors are buying locally. 
 
Table 13 Price comparison of 15 most common drugs - market survey, 2004 
 Drug Name Priv 
Phar 
in 
SDD 
Pop 
Phar 
in 
SDD 
CMSP
O 
in 
SDD 
 
RDF 
in 
SDD 
 
Priv/ 
RDF 
Pop/
RDF 
PMS
C/R
DF 
Priv/C
MS 
1 Disposable syringe 5cc 24 25 20 20 1.2 1.3 1 1.2 
 
25 20 20 1.2 1.3 1 1.2 
2 Amoxicillin Caps 
250mg 
117 158 75 100 1.2 1.6 0.8 1.6 
3 Paracetamol 500mg 
Tabs  
46 48 20 20 1.5 1.6 0.3 2.3 
4 Metronidazole 250mg 
Tabs 
77 53 27 29 2.7 1.8 0.9 2.9 
5 Ampilclox 500mg Caps 256 275 205 218 1.2 1.3 0.9 1.2 
6 Chloroquine 200mg inj 86 98 50 50 1.7 2.0 1.0 1.7 
7 Acetyl salicylic acid 
300mg Tabs 
98 65 15 15 6.5 4.3 1.0 6.5 
8 Ibuprofen 200mg Tabs 98 98 40 68 1.4 1.4 0.6 2.5 
9 Disposable syringe 2cc 24 25 20 20 1.2 1.3 1 1.2 
10 Chloroquine 150mg 
Tabs 
86 98 50 50 1.7 2.0 1.0 1.7 
11 Erythromycin 250mg 
Tabs 
248 286 205 175 1.4 1.6 1.2 1.2 
12 Indomethacine 25mg 
Caps 
121 112 - 68 1.8 1.6 - - 
13 Chlorpheniramine 4mg 
Tabs 
71 86 35 50 1.4 1.7 0.7 2.0 
14 Co-trimoxazole Tabs 160 170 45 50 3.2 3.4 0.9 3.6 
                                               
10
 Note however that the CMSPO does not sell directly to patients: retailers add between 20 and 35%, 
so that end-costs to users will be higher than the figures quoted here per item. 
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15 Total(Average) 108 114 62 67 1.6 1.7 0.9 1.7 
 
 
In the health facility survey, 630 prescriptions were analysed (490 from health centres, 80 
from hospitals and 60 from People’s Pharmacies). It appears from this analysis that there is a 
lack of consistency of prices within facility groups. For uninsured patients, only 6 items on the 
RDF EDL (the list of 16 items which are supposed to be in stock at all times) were the same 
price across all of the reporting health centres.  In hospitals, no items had a standard unit 
price for RDF EDL drugs for uninsured patients and only one item had a standard price in 
People’s Pharmacies. This is significant because the health centres and hospitals are RDF 
outlets and should be selling at a uniform RDF price. 
 
The mean cost of the EDL drugs was found to be 28% more expensive in People’s 
Pharmacies, compared with health centres and hospitals. This reflects the mark-up which 
they add.   
 
In reviewing the prices of drugs for insured patients, there was a similar picture of variation, 
with only 3 items (19% of the RDF EDL) in the health centres having a standard price, 3 
items (11%) in hospitals and one item (2.5%) for People’s Pharmacies.  For the non-standard 
drug list, 3 items (11% of 28 items) were priced the same for uninsured patients, 10 items 
(37%) for hospitals and 2 items (7%) in People’s Pharmacies. 
 
In theory, insured patients are meant to pay 25% of the overall drug fee at point of service.  
Analysis of the health facility data supports this, though with some variation: analysis of the 
mean cost of 15 EDL items (excluding fefol) showed an overall range of between 23.5-26.4% 
of the full fee.   
 
The main conclusion is that the overall prices of the RDF, in comparison to those of private 
and popular pharmacies and the CMSPO, are significantly lower. Another significant finding 
was that People’s Pharmacies are not, on the whole, any cheaper than private pharmacies, 
contrary to expectations. The RDF should also investigate the small variations in prices that 
were found. 
 
Availability 
 
Reliable distribution and stock-keeping systems are an important component of the RDF, 
ensuring that the agreed drugs are available at all RDF outlets at all times. People’s 
Pharmacies and hospitals are supposed to receive weekly visits from the RDF, and health 
centres monthly ones, although additional visits can be organised if drug stock-outs are 
reported. 
 
Drugs availability used to be between 99-100%, according to project reports. 98% of all 
essential drugs were available at all RDF health facilities, according to the evaluation of 1998 
(Fundafunda, Bonface, 1998).The evaluation looked at current performance, using the 
results of the health facility survey. Based on the reported levels of routine stock and the 
number of stock-outs at the facility, the average stock availability by facility type was 95.6% 
for health centres, 100% for hospitals and 95.2% for the People’s Pharmacies. 
 
Given that there was an RDF policy for certain designated items to be in stock at all times, 
facilities were asked whether these were part of their routine stock.  77% of health centres, 
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83% of hospitals and 100% of People’s Pharmacies reported that the 16 items listed were 
routine stock.  
 
However, only three items of the EDL were in stock in all facilities at the time of the survey: 
benzylpenecillin (1 miu for injection), metronidazole (200mg tabs) and paracetamol (500mg 
tabs).  The items most frequently out of stock were cotrimoxazole suspension (35% of health 
centres) and ferrous sulphate/folic acid tablets (43% of health centres and 40% of hospitals). 
There were no statistically significant differences by location, rural/urban distinction, or re-
stocking frequency. 
 
Health centres and hospitals were also asked the total number of drug items in stock.  Total 
drug stocks reported varied from 18- 97 (mean 64) for health centres, 21-82 (mean 66) for 
hospitals and 80-160 (mean 120) for People’s Pharmacies. There were statistically 
significances differences when comparing locations and rural/urban areas. Respondents 
reported stock levels lower than actual stock found by the surveys teams in three health 
centres and one hospital. 
 
These findings suggest a need for improvements in distribution and stock ordering and 
record-keeping – availability of essential drugs appears to have deteriorated since previous 
studies. 
 
Procurement and quality assurance 
 
The RDF mainly relies on a restricted tender system, which is thought to reduce transaction 
costs and to give a smoother flow, though clearly this poses a risk of overcharging by 
suppliers. The quantities procured depend on the expected morbidity of various diseases and 
the average consumption of each drug during the last 12 months. In 2005, for the first time, 
some drugs were purchased through international tender from local agents, at lower cost. 
 
Where they are available at good quality, local manufacturers are preferable as they can be 
paid in local currency, transport costs are cheaper and the testing procedures are simpler. In 
1999, 78% of RDF drugs came from European suppliers of generic drugs (especially 
Missionpharma), 12% from the CMSPO, and 10% from local manufacturers (Gamaleldin 
Khalafalla Mohamed Ali, 2000). The figures for 2002 are given in table 14: overall 37% of 
RDF drugs were imported, and they remain around this level (36% for 2004). This overall fall 
is the result of the growth in the People’s Pharmacy business, which relies mainly on local 
importers. 
 
Table 14 RDF drugs, by source, 2002 
 
 RDF PPs Total 
 Amount in LS % Amount in LS % Amount in LS % 
Imported 
from 
abroad 
8,326,759,250 92% - - 8,326,759,250 37% 
CMSPO 128,169,910 1% - - 128,169,910 1% 
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Local 
producers 
259,401,940 3% 1,530,877,860 12% 1,790,279,790 8% 
Local 
importers 
341,964,820 4% 9,095,250,090 69% 9,437,214,910 42% 
RDF - - 2,584,932,000 19% 2,584,932,000 12% 
Others 178,500 0% 65,495,440 0% 65,673,940 0% 
Total 
200211 
9,056,474,420 41% 13,276,555,400 59% 22,333,029,810  
Total 2001 6,101,764,310 36% 10,810,617,610 64% 16,912,381,920  
Source: RDF annual reports 
 
In the late 1990s, 95% of imported drugs were routed through Port Sudan, which is cheaper 
than air transport, though emergency items still came through Khartoum airport. In 2002, 7% 
of the RDF drugs, by value, were air freighted in; this rose to 11% in 2003. This upward trend 
should be controlled, for efficiency reasons. 
 
Suppliers are required to provide a Certificate of Pharmaceutical Product, certificate of patch 
analysis and free sale certificate. The imported drugs are sent to the NDQCL for analysis. 
The drugs which satisfy their safety and quality assurance are sent to the RDF warehouse 
for distribution to health facilities. During the late 1990s, less than 1% failed to satisfy the 
safety and quality assurance criteria. The drugs were disposed of and the supplier replaced 
them free of charge. In 2003, however, 4% of the samples tested for approval failed the 
quality tests. This remains within acceptable levels, but should be monitored.  
 
There is also concern, within the RDF management, about increasing delays in approving 
releases of drugs and the threat of additional bureaucratic checks, which will increase the 
RDF’s cost and so, ultimately, the prices to consumers. 
 
Supervision of facilities and service quality 
 
Supervision of facilities was from the start of the RDF a key component of its work. This is 
undertaken by four teams for the health centres and one team each for hospitals and 
Peoples’ Pharmacies.  The team, comprising pharmacist, assistant pharmacist, two 
accountants and a driver, monitor financial performance and accountability, drug availability 
and consumption and ensure that the quality of pharmacy management adheres to National 
and International Standards.  The visits are intended to be routine and are also used as an 
opportunity for cash collection and cash book reconciliation. Occasionally spot-checks are 
done without prior notice. 
                                               
11
 In 2003, the reporting format was changed and this information is no longer published. 
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The health facility survey asked facilities about the regularity of visits by the RDF teams. The 
answers are shown in figures 1 and 2 below: they broadly comply with the RDF guidelines. 
They suggest that most health centres and hospitals are visited fortnightly, while People’s 
Pharmacies are most likely to be visited weekly. This reflects their rate of through-put, which 
is higher, requiring more frequent restocking. People’s Pharmacies are resupplied daily, 
twice weekly or monthly, while hospitals are resupplied weekly or monthly, and all health 
centres reported being resupplied on a monthly basis. 
 
For the health centres, those in Khartoum receive more frequent visits. Given the costs of 
transport to outlying facilities, this is one way of minimising costs. 
 
The frequency of RDF visits compares favourably with that of the MoH: only 8% of facilities 
reported RDF visits to be irregular, compared with 73% of MoH supervisory visits. The 
reported frequency of supervision by the KMoH has also decreased, from 42% of health 
centres and hospitals surveyed receiving a supervisory visit at least once per month in 1996 
to 28% in 2004.  
 
Figure 1 Frequency of supervision, by facility 
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Figure 2 Frequency of supervision, by location (health centres) 
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A key component of pharmacy management is documentation. Monitoring of documentation 
is an element of the RDF supervision. Only 8% of health centres that responded to the 
question maintained daily stock records and stock cards and only one out of six of the 
hospitals.   Only one People’s Pharmacy reported having a copy of the National Essential 
Drug List, compared to 100% of health centres and 5 (out of 6) of the hospitals. 
 
 
Training and operations research 
 
The RDF has a long tradition of investing in human resource development and training, both 
before hand-over and since.  Examples in recent years include the following: 
 In 2001, 250 pharmacy staff at health facilities received short training courses in 
dispensing and counselling skills 
 Weekly seminars on drug supply management were held for RDF and hospital 
pharmacists in 2001-2 
 The RDF held subscriptions to international journals and distributed textbooks and 
formularies regularly to pharmacists in facilities and People’s Pharmacies  
 A prize of excellence was introduced in 1998, to encourage good practice 
 Refresher courses were run on topics such as drug management and rational drug use; 
quality assurance; therapeutic drug monitoring; drug and therapeutic committees in 
hospitals; and drug information 
 The RDF also supported the establishment of a Pharmaceutical Services Management  
specialisation within the Sudan National Board of Medicine, and helped to set up a short 
course in Drug Supply Management and Rational Use of Drugs, in collaboration with 
CEDMAP, in Nairobi, Kenya 
 
It is important that this focus on quality is continued. 
 
Although operations research was one of the original mandates of the RDF, it has in recent 
years focussed on its ‘core business’ of supplying drugs and recouping costs and has 
neglected gathering health information and carrying out research. This area should be 
strengthened, as it would allow the RDF to carry out high quality monitoring and evaluation of 
its own work, rather than relying on periodic external studies. Some training in operations 
research and statistical analysis might be required for the RDF staff to carry this out. 
 
Summary of findings on pharmaceutical issues 
 
Many of the systems – for procurement, quality assurance, distribution and stock control – 
continue to operate effectively. In addition, the market survey confirms that the RDF 
continues to offer lower prices to its clients, compared with alternative outlets. However, 
there are some areas of concern, notably: 
 That the full range of essential drugs is not available in all RDF outlets - the proportion of 
available stock in the facility has reduced from a reported 100% in health centres in 1996 
and 2000 to 95.6% in 2004   
 That prices, while lower on average for the full list, are higher compared with the CMSPO 
for the 15 most common drugs, and, moreover, are not the same for all RDF outlets 
 That some indicators of rational drugs use have deteriorated (e.g. over-prescription of 
antibiotics)  
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 That systems for stock-keeping appear to be relatively poor in many of the RDF facilities 
– the number of health facilities stocking expired drugs has risen from 16% in 1996 to 
28% in 2004. These raise questions about the quality and robustness of the supervision 
which is being undertaken 
 That the RDF sales of non-essential drugs are growing, disproportionately. While driving 
up profits, there is a real risk that the RDF mandate of promoting rational prescribing will 
be overshadowed by this trend. 
 That there is a need, with the FMoH and KMoH to review the NEDL, to ensure that it is 
up-to-date with current prescribing practice 
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5. Access and exclusion 
 
This section looks at the following questions: 
 how many people are being served by the RDF? – trends in utilisation 
 geographical access – are RDF services within reach? 
 how many households, and what kinds of households, cannot afford to access RDF 
drugs and health services? 
 how much awareness is there in the community of the RDF? 
 what is the level of community participation in health services generally? 
 
Utilisation trends in health facilities 
 
Table 15 shows the trends in utilisation of RDF facilities between 1996 and 2002. It is 
impressive to note that 3 out of 5 of the population of the state were using RDF facilities in 
2002 – some 3 million in total. As seen in the figures for revenue, People’s Pharmacy 
attendances are outnumbering treatment facility users. All trends are upward until 2003, 
when a small decline is shown by both People’s Pharmacy and health facility attendances. 
This trend of decline continues into 2004 and 2005, at least for RDF facilities. This decline is 
attributed by the management to the combination of absent staff in health facilities, as well as 
the issues, already documented, with the KHIC/FHIC and the need for updating of the NEDL. 
These issues should be addressed, as a shift from RDF to PP outlets means fewer essential 
and generic being consumed, and consumers paying higher prices. 
 
Table 15 Total attendances at RDF-supplied facilities, 1995-2003 
Year 
Khartoum 
State 
population 
Total 
attendance 
at all RDF 
supported 
facilities 
Attendance 
at RDF 
treatment 
facilities 
Attendance 
at Peoples 
Pharmacies 
1995 3,636,907      
1996 4,005,460 
         
683,069  
           
683,069    
1997 4,184,677 
         
940,430  
           
940,430    
1998 4,372,340 
       
2,193,598  
        
1,202,499  
           
991,099  
1999 4,568,177 
       
2,483,440  
        
1,027,883  
           
145,557  
2000 4,740,000 
       
2,976,887  
        
1,131,544  
         
1,845,343  
2001 4,936,000 
       
3,030,996  
        
1,264,845  
         
1,766,151  
2002 5,139,000 
       
3,075,728  
        
1,324,111  
         
1,751,617  
2003 5,352,000 2,842,760 1,189,826 1,652,934 
2004  2,794,644 1,112,712 1,681,932 
Source: (Gamalgeldin, K. M. & Fundafunda, B., 2004) and annual reports 
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In the health facility survey, mean total attendance was relatively low - 29 OPD per day for 
health centres and 121 for hospitals. Hospitals in urban areas had higher OPD and 
admission rates, but there was no significant difference for health centres, between rural and 
urban areas. Bed occupancy was also low for hospitals surveyed – 20% on average. This 
leads to relatively inefficient use of staff and resources. The mean number of OPD cases per 
day per 1 medical staff was 9.8 in health centres and 3.5 in hospitals. This has implications 
for the RDF and explains why sales volumes are higher through People’s Pharmacies (PPs 
can dispense drugs prescribed at health facilities, as well as selling over the counter drugs). 
 
Geographical access 
 
In 2002, the RDF supplied 22 public hospitals managed by the KMoH in KS, 102 public 
health centres and all of the former MoH-run People’s Pharmacies (18 out of a total of 77 
People’s Pharmacies, many of them commercial outlets on a par with the 565 private 
pharmacies in KS). The main exceptions, in terms of public facilities, were the 19 public 
hospitals which are run by institutions other than the KMoH: these are mostly run by the 
FMoH or other ministries and are stocked mainly by the CMSPO.  Since then, there has 
been further expansion of the RDF network, with the addition of another 11 health centres, 
with plans to add 10 more in 2006. 
 
However, there are now some 35 health centres – mostly in remote areas and covering a 
small population – which are outside the RDF network. These would be expensive to supply 
and would provide only a small through-put, but the RDF should be looking for innovative 
ways of extending its reach to them. Their current drug supply – as for much of Sudan – 
relies on health staff purchasing drugs in the market and re-selling them at a profit to 
patients. In terms of quality and price, this is a loss to the consumer, compared to the RDF. 
Although the total population excluded in geographical terms is not very great, it infringes the 
basic principle of the RDF, which is to supply all public facilities, however remote and 
unprofitable.  
 
The health facility results suggest a reasonable degree of geographical equity in terms of the 
facilities and their quality.  There were very few significant differences in the results by 
location and rural/urban status, in terms of numbers of staff, essential medical equipment, 
range of service, drugs availability and RDF supervision. The main rural/urban difference 
was in frequency of MoH supervision, with urban facilities being supervised more frequently.  
 
Previous evaluations noted that all RDF health facilities are within walking distance 
(AwadElKarim, Professor M. A., 1996). Our household survey looked at this issue by 
examining the time that households had taken to reach their chosen treatment centres. The 
mean time to reach health centres was 15 minutes. Public hospitals were the most distant, 
on average, at 34 minutes. Only a few outliers, in rural areas, took an unacceptable period of 
time – three hours to reach a hospital and two hours to reach a health centre were the 
maximum times recorded. 
 
Financial access 
 
The main barrier to access in Khartoum State is financial, rather than geographic. Sudan 
operates a cost-recovery system in which an extremely high proportion of health costs are 
borne by households. According to World Bank figures for 2003, government funding 
contributes a mere 20% of total health expenditure, compared with the average of 41% for 
Sub-Saharan Africa, and of that, the vast majority is out of pocket payments. This imposes 
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huge costs on households, and drugs are a major component of those costs. There are no 
national estimates for expenditure by households on drugs, but our household survey 
suggests that they account for 58% of total household expenditure on health care (Witter, S. 
& et al., 2005). This is not an unusual proportion: up to 80% of household spending on health 
is absorbed by drugs in some countries (Quick, J. D. & et al., 1997). 
  
 
 
 
 
HEA results: ability to pay of different groups 
 
Table 16 summarises the results of the HEA, in terms of ability to pay for health care and 
drugs of different groups within KS. 
 
 In the HEA (Adams, L. & et al., 2004), the IDPs are identified as amongst the most 
vulnerable, and the least likely to afford health care. IDP “very poor” and “poor” households 
(together they make up 60-75% of the IDP population) are unable to meet their basic needs 
(including health care) for some or all of the year (see figure 3).  The only way they could 
meet their basic needs would be if children worked full time instead of going to school.  As it 
is, households cut down on essential spending (such as non-staple food items) to make ends 
meet.  The rainy season is a particularly hard time as expenditure increases while incomes 
decrease.  It therefore goes without saying that they are unable to meet health costs on their 
own.  They may receive assistance for low-cost treatments, but they are likely to leave 
treatment till the last minute, or (if an adult) to go without treatment. 
 
IDP “middle” income households (25-35% of the IDP population) are able to meet their basic 
needs all year round but are unable to meet the cost of emergency and complex health care 
without support from relatives and sometimes loans.   
 
“Better off” IDP households (0-5% of the IDP population) have no problems meeting their 
basic needs, including health care costs.  
 
The urban “very poor” are unable to meet the cost of their basic needs by themselves but 
most receive gifts from relatives and some get Zakat support.  These households benefit 
from close family ties and living within extended families in large plots.  While this group is 
usually defined as “vulnerable” and includes widow-headed households, there are many 
widows who benefit from the support of a son or daughter living in the same house. 
 
The “poor” urban group are self-sufficient in terms of their basic needs but face difficulties 
with paying for high-cost heath care for which they apply for Zakat assistance or seek 
assistance from relatives.   
 
“Middle” and “better-off” households have no difficulty in meeting their basic needs or 
accessing health care; they usually visit private rather than public facilities and the “rich” may 
go abroad for health care. 
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Figure 3 Income-expenditure comparison, HEA 
Income-Expenditure comparison for Urban and IDP 
households
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For rural households, the “vulnerable” group may have difficulty meeting their basic needs if 
they are not well supported by relatives.  These households are those without land, who 
have only one or two income earners, who are dependent on unskilled labour but who are 
living in areas isolated from labour opportunities, and where agricultural production has 
declined due to inefficiencies in the irrigation system (perhaps a government-managed 
system) or other similar problems.   
 
“Poor households” in rural areas are likely to meet their basic needs but may have difficulty 
accessing emergency health costs on their own – although they are may be able to get help 
through Zakat and/or gifts within the community.   
 
Other rural households (farmers, livestock keepers, traders) have no problem accessing their 
basic needs or health care costs. 
 
Table 16 Ability to meet basic needs and emergency health care: HEA results for KS 
 
 Urban IDP Rural Khartoum 
State 
Summary 
% of State 
population (estimate 
based on key 
informant 
discussions) 
70% 20% 10% 
% of each livelihood 
group who cannot 
meet their basic 
needs for all or part 
of the year 
5-10% of 
urban:   
 
The 
“vulnerable” 
(mainly 
households 
with one 
earner)  
60-75% of IDPs:  
 
10-15% 
(“vulnerable”) + 
50-60% (“poor” -
unskilled labourer 
households)  
5-10% of  rural: 
The “very poor”.  
These households 
live in inaccessible 
areas, don’t own 
land and rely on 
unskilled labour 
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Overall % of 
Khartoum State 
population who 
cannot meet basic 
needs for all or part 
of the year 
 
2% 
 
 
14% 
 
1% 
 
17% 
PLUS 
% of each livelihood 
group who can meet 
basic needs, but 
who can’t meet the 
cost of emergency 
health care without 
assistance 
22%  of urban 
 
The “poor” 
(unskilled 
labourers) 
30% of IDPs 
 
The “middle” 
(skilled labourers/ 
low-paid salaried 
workers) 
30% of rural  
The “poor” (these 
households rely 
on unskilled labour 
but live in more 
accessible areas 
so with better 
opportunities.   
 
Overall % of 
Khartoum State 
population who can’t 
meet the cost of 
emergency health 
care without 
assistance. 
 
15% 
 
6% 
 
3% 
 
24% 
 
 
This study has shown that there are major differences in livelihoods between the different 
groups, and that the households living in poverty (17% overall) are found predominantly in 
IDP camps.  There are other important problems facing many IDP households (see HEA 
report), which this evaluation cannot list in detail, but many relate to their insecure 
“residential” status as IDPs, which continues, despite the peace process. 
 
Access to health care in terms of availability of providers is reasonably good, with NGOs 
(national and international) running health centres in most IDP camps and providing drugs 
and services at lower costs than the private sector.   However, most “poor” households 
cannot afford to pay for health care for their families.  A case of malaria requires spending 
about SDD 1,000 (about US$4) for registration, consultation, test and drugs – equivalent to a 
day’s pay for labourers.  Little evidence was found of “poor” IDP households benefiting from 
the Zakat fund.  Health care which is not affordable at the time of need means that treatment 
is delayed until the last minute – which carries risks of mortality.   
 
Ability to pay: household survey results 
 
Income levels and poverty 
The household survey confirms that poverty levels are high in Khartoum State. 51% overall 
are found to be living in conditions of absolute poverty, while in the most disadvantaged IDP 
areas, the rate is 66%. Inequalities are also high: households in richer areas have an income 
four times larger than the IDP households, and two and a half times larger than households 
in poor urban and rural areas.  
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In addition to having lower incomes, IDP households are disadvantaged in terms of access to 
infrastructure. They travel the furthest to reach health facilities (47% travel more than 1 km, 
which is far relative to other groups, though not far by comparison with other countries and 
rural areas). Access to water and electricity is also very poor for this group: only 14% have 
electricity and less than 6% running water, compared with nearly universal coverage in the 
wealthier areas. The costs of purchasing water amount to one fifth of an average IDP 
household’s income. 
 
Ill health 
Ill health affects all of the population – 80% of households reported at least one illness in the 
past fortnight, with an average of 1.5 episodes per household. The duration of illness does 
not appear to be linked to economic status: mean duration is 7 days, with no significant 
variation by area or income. Poor areas report significantly higher rates of illness though, as 
do women: double, on average, at of men for all quintiles and for most age groups and 
illness types. 
 
The main illnesses are respiratory problems, malaria, diarrhoeal illnesses and injuries. Some 
illnesses, like TB, seem to be under-reported, perhaps due to stigma. The pattern of illness 
varies by age group and area. IDPs are more likely to suffer from conditions linked to poor 
environmental conditions, such as water-borne diseases and diarrhoea. 
 
Treatment strategies 
A large proportion of those who fall ill are treated – 94% overall – and physical access and 
waiting times are good within Khartoum State. Responses to questions about quality are also 
positive. Financial barriers are very real however, as shown by the fact that nearly 40% of 
non-treaters are found in the bottom quintile and 100% of respondents in that quintile cite 
lack of money as the reason for not seeking treatment. If home treatment and visits to 
pharmacies are combined, 20% overall self-medicate, presumably to reduce time and 
financial costs.  
 
The choice of facility is affected by income, with richer households more likely to use private 
pharmacies, clinics and hospitals, compared with poorer households, which rely on the public 
health centres, public hospitals and NGO facilities. Overall, public health centres are the 
most common treatment centre (36% of episodes), followed by public hospitals (29%). In 
88% of cases, care is sought more than once for a given episode of illness. 
 
No evidence of discrimination against particular age groups or by sex was shown for 
treatments in the past fortnight. However, 85% of reported admissions in the past year were 
for men, which is very different to the more general illness figures (38% men; 62% women). 
This may be related to their unwillingness to present for treatment at an earlier stage of the 
illness (which was confirmed by focus group discussions). 
 
Health care expenditure 
According to the Federal Ministry of Health, the last household survey of health expenditure 
was carried out in the 1970s (NCMH Secretariat, 2004). The information from this survey is 
therefore very valuable to the health policy debate in Sudan, even though it provides insights 
into the situation in Khartoum State alone. 
 
Various sources concur that household expenditure forms the bulk of total expenditure in 
Sudan – estimates range from 70-80%, or 15-20 USD per capita annually. However, our 
survey suggests that, for Khartoum at least, private expenditure is much higher. Our figures 
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suggest an average per capita annual expenditure of more than $57. It should be noted that 
this is likely to be an underestimate of total private spending as contributions into insurance 
schemes were not included and there may have been more than two care episodes for the 
particular illnesses reported (the survey asked about the first and second treatments: 88% 
sought care a second time, and many probably sought care several times for the same 
illness). 
 
Average direct expenditure for one treatment episode is roughly 34,000 SP, but this 
increases significantly with household wealth, reflecting mainly a more expensive case mix 
and choice of more expensive treatment facilities. (Average spend per episode in IDP areas 
is one-seventh that of high income urban households.)  
 
In relation to household income, total health care spending constitutes 11%, which would be 
classified as ‘catastrophic’ by most definitions. (Definitions of ‘catastrophic’ levels of health 
expenditure vary, but usually start from 5% of total expenditure and upward (Xu, K. et al., 
2003). All groups are spending a high proportion of their income on health care – the largest 
proportion was 15% for IDPs, but differences between areas were not found to be significant. 
 
Self medication is the cheapest option, followed by health centres and public hospitals. In 
terms of inputs, drugs are by far the most expensive component on health care, accounting 
for an average of 58% of total direct costs. Costs also vary by illness type, with some 
conditions such as diabetes emerging as three times more expensive than the mean. 
 
Only one-fifth of households affected by illness reported indirect costs (lost income and 
carers’ costs), but these were often high. Averaged across all episodes (including those with 
no indirect costs), indirect costs add 9,000 SP to the cost per episode. IDPs report higher 
average indirect costs, as do chronic illness sufferers (such as TB patients). 
 
It is striking that no preventive services were 100% free: 5% reported paying for 
immunisations; 20% reported paying for post-natal check-ups; 70% reported paying for 
antenatal check-ups, and 100% reported paying for family planning.  Both the existence of 
prices for preventive services and the general unpredictability of prices are likely to reduce 
consumption of these goods below socially desirable levels and contribute to poor 
performance towards development goals (Decaillet, F., Mullen, P., & Guen, M., 2003). 
 
Coping strategies 
Financial barriers are a major problem in Khartoum, as evidenced by the 29% of households 
which are unable to pay for health care. These are heavily concentrated in the poorer areas. 
In IDP areas, 46.5% are unable to pay. 
 
Borrowing from friends is the most common coping strategy (57% overall), and is the main 
one adopted by all income groups. While the higher income households are able to rely on 
borrowing and savings alone, poorer ones used a wider range including reducing on 
treatment, owing money to facilities, reducing expenditure and borrowing from money-
lenders. All of these strategies by poorer households have potential long term negative 
effects. 
 
Official protection for indigents exists but is limited in scale. Only 1% of those unable to afford 
treatment received an exemption: one of these cases was in the bottom quintile and one in 
fourth. Health facilities appear to have discretion over the operation of exemptions. 3% 
received assistance from the Zakat Fund and from Takaful. These cases fall in the bottom 
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quintiles. Qualitative information suggests that accessing these funds is complex and 
unpredictable. The household survey and qualitative methods all point to informal networks 
as the most important form of social protection. 
 
Insurance coverage 
Insurance coverage, and particularly the national health insurance scheme, is of growing 
importance in Sudan, but still only benefits the minority. 23% of households (but only 9.3% of 
individuals) had some sort of insurance coverage in this survey. Membership is highest in 
middle income, poor urban and rural areas, and lowest in high income and IDP areas. The 
biggest scheme is the KHIC (Khartoum Health Insurance Corporation), which accounts for 
69% of the insured; the next largest scheme is the organised forces one, with 21% of the 
market share. Only 49% of members benefited from the insurance in the latest episode of 
illness. This may be explained by the fact that KHIC membership is compulsory for public 
servants, and yet only 50-60% of facilities are enrolled in the scheme. The rich may also 
choose to opt for higher quality care, despite being enrolled in the national scheme. 
 
Membership of an insurance scheme does not reduce expenditure (members spend 2 ½ 
times more on average than non members, per episode), but does increase the likelihood of 
treatment and of treatment at more expensive facilities. It seems then that moral hazard is an 
issue, but overall utilisation at this stage (average of 1 visit per person per year) is still low, 
suggesting that insurance is acting to relieve suppressed demand rather than to frivolous 
use.  
 
The results of the household survey are broadly consistent with the HEA results, and suggest 
that the numbers excluded are higher than the 8% who could not afford medicines, according 
to 1996 evaluation. That figure was based on the proportion of prescriptions written but not 
filled, which of course neglects all of the sick people who never attend health facilities, 
because of financial or other barriers, as well as including those who pay but have to make 
unacceptable sacrifices to pay the bills. Our figures suggest that 29% of the overall 
population cannot afford to pay for health care, of which the drugs cost is the major 
component. 
 
"Our people are very poor and they suffer from many diseases. They can't pay for health 
services. If you want to help them provide them with free HS and free drugs as they are poor 
and sick. Low cost drugs will not solve their problem. They can't pay even for the entrance 
ticket" (KI in IDP camp)   
 
 
Links with the community and levels of community awareness 
 
According to the household survey results, awareness of the RDF within the community is 
indeed low (as suggested by some, but not all, of the previous evaluations). Only 10% 
claimed to know about the RDF, and 6% were able to give some description of what it did. 
9% reported that their families had benefited from it. 
 
Awareness was highest in poor urban and rural areas (see figure 4), which are the main 
constituencies for the RDF. As the IDP camps have mainly been served by NGO services, it 
is perhaps unsurprising that awareness of the RDF was not high there. 
 
FGD informants corroborate this lack of awareness. Although many were using RDF 
facilities, few had heard of it or knew what its function was. 
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Figure 4 Distribution of respondents who are aware of the RDF 
Distribution of respondents who are aware of the 
RDF
Urban poor
35%
Rural
26%
Urban middle 
income
19%
Urban high 
income
10%
IDP
10%
 
 
If the RDF has a relatively low profile in the community, is this of concern? On one level, if it 
is operating in a businesslike fashion, supplying drugs efficiently and at relatively low cost, 
there is no great need for the public to be aware of the mechanism through which that is 
happening. 
 
There are two reasons why greater communication with the public is important: 
 as a programme with public health goals, the RDF needs to maintain a focus on rational 
prescribing, which means that the public need to be informed. The RDF could provide 
more information on disease management, the importance of taking following proper drug 
regimen etc., for display in public facilities. These materials are currently lacking. 
 if any systems for exemptions are introduced, these have to be discussed with and 
publicised through community channels. 
 
The health facility survey looked at the mechanisms for community participation in health 
facility management. 73% of the health centres and 50% of the hospitals reported having a 
functioning community health committee (CHC), but only 33% and 20% respectively had 
minutes of the meetings (see table 17), which suggests that this may be a more realistic 
figure for active CHCs.  For the health centres with active committees, some 70% hold 
monthly meetings, and the other 30% meet weekly.  
 
In 1996, 47.3% of health facilities surveyed had a CHC but the level of community 
participation was considered to be minimal and inadequate.  Comparing those figures with 
the 2004 ones, it appears that there is a higher proportion of facilities with a CHC (69% 
overall), but probably little improvement in the level of activities (only 31% having regular 
meetings).  
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Table 17 CHCs in health centres and hospitals 
  
 
Summary of access findings 
 
Utilisation trends have been impressive (the RDF reaching 3/5 of the total population of 
Khartoum State in 2002), but may have declined slightly in the last few years. Changed 
reporting by the RDF makes it harder to track some of these issues. 
 
Geographic coverage is good, but a plan should be developed to reach the remaining remote 
health centres. The same kind of model should be used as for existing facilities, but perhaps 
with less frequent supervision (rather than selling drugs as a consignment, which shifts the 
risk on to the facility and also opens the way for higher mark-ups to be added). 
 
Financial access is the main issue of concern, with the health sector charging for almost the 
entire range of health services and also, of course, the drugs. HEA findings suggest that 17% 
of households in Khartoum State are unable to afford basic health care costs, and 24% can 
meet basic costs but are unable to meet ‘emergency’ costs, if they arise. These households 
are mainly IDP ones (60-75% of whom are estimated to be unable to meet their basic health 
care costs), plus the poorest 5-10% of the urban and rural households. 
 
The household survey results find that 6% of the sick overall do not treat (largely for 
economic reasons), and that 29% of those who do treat cannot afford to pay for their 
treatment, resorting largely to borrowing or reduced treatment. For the IDP areas, this is 
much higher (46.5%). 
 
These results relate to overall health care costs – not just drugs costs – but drugs form the 
bulk of health care expenditure, according to our survey, accounting for just under 60% of 
total costs. 
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ANALYSIS AND CONCLUSIONS 
  
6. Analysis 
 
This section discusses the following issues: 
 Whether the RDF has been successful, and, if so, why 
 Whether the RDF is still relevant and necessary in Khartoum State today 
 How access might be improved in Khartoum State 
 Implications and insights for national roll-out 
 
The RDF – a success story? 
 
The most common pitfall with revolving drugs funds is that they fail to revolve (Cross, P. & et 
al., 1986). Common reasons for this include: 
 Undercapitalisation 
 Prices set below replacement costs 
 Delays in cash flow 
 Rapid programme expansion without sufficient additional capital 
 Losses due to theft and deterioration 
 Unanticipated price increases due to inflation and changes in parity rates 
 Foreign exchange restrictions 
 
The RDF has passed this first hurdle. It is clearly viable, nearly a decade after hand-over 
from Save the Children UK. It has taken over full costs since being handed over by Save the 
Children (UK); it has expanded its network; it has expanded coverage; and it has maintained 
its cost advantage over rivals. 
 
From the beginning, the RDF had to balance business-mindedness with a commitment to 
public health goals. The key elements which have promoted its success as a business are: 
 The substantial and phased investments by Save the Children UK, not just in drugs but 
also in training, infrastructure and systems development 
 Its long period of development: it was ten years before it was expected to be autonomous 
 The early emphasis on efficient systems (e.g. defined roles and responsibilities for staff) 
 Sustained political support, at the highest levels in Khartoum State, which have enabled 
the RDF to manage external threats (e.g. to its financial independence) 
 The tax exemption from customs duties, which enables it to undercut competitors’ prices, 
at least for imported drugs 
 The underlying strength of the Khartoum economy, which enables the majority of the 
population to afford drugs at RDF prices 
 
However, the RDF had a mandate that went beyond financial sustainability. Its goal was also 
to promote appropriate and rational drug use. It aimed to do this through: 
 Its internal cross-subsidies, from high-volume sales through the People’s Pharmacies  to 
supplying public health centres; from common cheaper drugs to more expensive ones; 
from central facilities to more distant rural ones. 
 Its focus on PHC services, covering all of the public health centres in the State 
 Its emphasis on rational prescribing and the use of essential drugs  
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At any one time, the RDF risks losing its focus on the business side (leading to financial ruin) 
or the public health side (leading to it becoming a self-serving enterprise, run for the benefit 
of staff or shareholders, rather than patients). It is not an easy balance to maintain. To date, 
the record looks good. 
 
There are, however, threats to both financial sustainability and the RDF’s public health goals. 
Potential financial threats include the following: 
 
 Failure to maintain effective systems for cost control, especially for pay and incentives 
 Further increases in wastage and failure to address stock-keeping problems at facility 
level 
 Failure to recoup debts, which could threaten the RDF’s hitherto good reputation with its 
suppliers 
 Loss of independence, in the form of political interference or even greater resource 
extraction by the KMoH 
 Adverse developments for its chief client, the KHIC. The RDF and the KHIC in KS are 
now co-dependent: the KHIC relies on the RDF to provide reliable and affordable drugs 
to its clients; and the RDF is increasingly reliant on the KHIC to boost demand for its 
products. (In 2000, 29% of patients in RDF facilities were covered by health insurance; 
the figures for 2003 were 32% for hospitals and health centres, and 38% of People’s 
Pharmacy users). The proportion of RDF revenue coming from the KHIC was 32% in 
2000; now it is 56%) If the HIC were to go out of business or fail to pay its bills, that would 
cause an immediate financial crisis for the RDF. 
 
Potential threats to its public health mission include: 
 Broadening of drugs list to the extent that essential drugs become a minor component  
 Failure to fund community and practitioner education on rational prescribing 
 Failure to support measures to extend access in geographical terms and for the  
population which is unable to afford basic drugs at current prices  
 Becoming too focussed on profitability, so that the quality of service to outlying and less 
profitable health centres is neglected 
 
Competent and committed leadership is the key to managing these threats. 
 
Is the RDF still needed? 
 
Some of the original reasons – dating back to the mid-1980s - for the creation of the RDF no 
longer exist. Hard currency in Sudan is no longer so constrained. The local pharmaceutical 
market is more developed.  There are more trained pharmacists available now. The health 
care system, with its user fees and health insurance cover for some, has greater liquidity. 
The Central Medical Supplies – the governmental body with responsibility for pharmaceutical 
supplies throughout the country – is more organised. In this changed context, it is worth 
asking what value-added the RDF contributes, as it is presently functioning. 
 
It is also important to recognise the costs. The RDF runs a relatively efficient drug supply 
service for the public health centres and hospitals, made possible in part by a unique 
customs tax exemption. This is a transfer from the Government of Sudan to the sick of 
Khartoum State. Whether this transfer is optimal depends on what alternative use that money 
would have been put to. There is definitely a case for arguing that the resources could be put 
to better use in the poorer, more remote States. However, we are not confident that the 
resources would find their way there, given the current system of health financing, which 
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places responsibility on States to finance the recurrent costs of health care out of their own 
resources (Decaillet, F., Mullen, P., & Guen, M., 2003).  
 
It also depends on who is using the RDF services. Utilisation trends suggest that coverage of 
the RDF is good. Our household survey also suggests that public facilities – health centres 
and hospitals – are widely used. Of the actions taken in case of sickness, visiting the public 
health centre was most popular on average (36%), closely followed by public hospitals 
(29%). Use of health centres is concentrated in the bottom three quintiles, while investment 
in public hospitals benefits the bottom four quintiles most.  
 
Overall, only 6% of those reporting sickness failed to treat, which is relatively low. On the 
other hand, those in the bottom quintile were nearly five times more likely not to treat than 
those in the top quintile, while 29% overall were unable to afford their health care costs. 
Clearly, there is a role for more pro-poor measures, either directly through the RDF or 
through other mechanisms. 
 
One way of investigating the value-added of the RDF is to compare the value of the tax 
exemption it has (worth 17.5% of imported drugs’ value) with the extent to which it undercuts 
its nearest rival (prices on average 40% cheaper than the CMSPO – and this applies across 
the whole range of drugs, while the tax exemption only covers the 37% of RDF drugs which it 
imports). This suggests that the RDF continues to be relatively efficient and to provide social 
benefits in excess of its fiscal costs.  
 
In addition, the RDF operates an equal price list across the state, which benefits more 
outlying and rural areas, and passes on transfers worth 210 million SDD each year to the 
MoH. These transfers alone are larger than the value of the tax exemption which is granted 
on its imports. Seen in this way, the tax exemption is more of a gift to the KMoH. 
 
The RDF also provides a free service of handling, storing and distributing the free emergency 
drugs which the Ministry of Finance provides to assure free service in the first 24 hours of 
hospitalisation, and handles procurement for some public health services, such as the 
malaria programme. 
 
Within Khartoum, the main alternative to the RDF are the People’s Pharmacies and private 
pharmacies, which purchase mainly locally produced goods and are limited by law to a mark-
up of 20%. There is some anecdotal evidence that they have relocated themselves to avoid 
close proximity to RDF outlets. 
 
The People’s Pharmacies were originally set up in opposition to the private pharmacies, 
which supplied mainly brand name drugs at higher prices. The People’s Pharmacies, by 
contrast, mainly purchased and sold generics. Since 2000, however, the CMSPO has been 
selling generics to private pharmacies and hospitals as well, reducing the distinction between 
the private pharmacies and People’s Pharmacies (Graaff, P. & Everard, M., 2003).  
 
Our market survey confirms that People’s Pharmacies are selling at prices that are 
comparable to private pharmacies (despite the original regulations that stipulated that 
People’s Pharmacies should set prices at 5% below the private sector), which are, on 
average, twice as expensive, item per item, as the RDF ones. The prescription review in the 
health facility survey found an even bigger discrepancy, with the mean cost of a prescription 
in a People’s Pharmacy four times as high as the health centres and hospitals. This is 
unlikely to be explained by the number of drugs prescribed, as the mean was just under 2 
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items per prescription and the only facility group which was significantly lower was the 
hospitals. This suggests that People’s Pharmacies are probably providing more expensive 
versions of drugs. This is linked to insurance – more of the PP prescriptions were for insured 
clients, compared with health centre and hospital prescriptions. 
 
Despite early fears that the RDF would drive the private sector out of business, it appears 
that the People’s Pharmacies and private pharmacies are still numerous – 565 private 
pharmacies and 77 People’s Pharmacies in KS at the time of our market survey - and doing 
good business. This is despite the fact that they are disadvantaged relative to both the RDF 
and the CMSPO, which benefit from tax breaks, can set their own prices, have monopolies 
over public outlets and can sell unregistered drugs. 
 
To summarise, it seems clear that though the original conditions which necessitated the 
development of the RDF no longer apply, it is continuing to fulfil its original mandate and is 
providing high quality, appropriate essential drugs at lower cost than the market alternatives, 
as well as a range of other public services.  
 
Options for improving financial access within Khartoum 
 
At present, the RDF provides below-cost essential drugs across Khartoum State, but it 
operates on a strict cost-recovery basis. Those who are unable to afford drugs are denied 
access, and formal social support systems are limited.  
 
In our household survey, when asked how they coped when unable to pay for health care, 
3% reported receiving charitable donations, 3% got assistance from the Zakat, while 1% 
were given an exemption by the facility. The Zakat and charitable donations were 
predominantly reported in the bottom quintiles, while exemptions were equally divided 
between the bottom quintile and the top. In focus group discussions, a variety of voluntary, 
informal mutual support mechanisms emerged as most significant (as reflected in the high 
reliance on borrowing to cope with health care costs, which applies across the different 
socio-economic groups). 
 
There are many different options for improving access, including: 
 Altering the cross-subsidies, within the RDF 
 Expanding health insurance coverage 
 Extending national exemptions and free programmes  
 Extending community health financing schemes 
 Reforming existing social protection mechanisms, in particular the Zakat 
 Increasing central funding for health care and decreasing patient contributions generally 
 
These will be discussed in turn. 
 
Some of the discussion here relates to user fee costs, as well as drugs costs. Although the 
issue of user fees might not appear directly relevant to the RDF, any measures which 
decrease or spread health care costs will free up household resources for drugs and so 
improve access in terms of the RDF’s function. 
 
Altering the cross-subsidies, within the RDF 
The RDF has to operate on a cost-plus basis, making sufficient money overall to cover its 
costs and generate a small surplus for reinvestment. There is relatively little scope then for 
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exempting patients, unless external subsidies are made available. It would make sense for 
this to be done through the health insurance system, so that poor households not only 
reduce their drugs costs, but also gain access to free services. Already, according to our 
household survey, 20% of households are self-treating (either taking no action, preparing 
home remedies, or visiting People’s Pharmacies and private pharmacies). Exemptions 
schemes should encourage households to get a consultation before treating. 
 
Expanding health insurance coverage 
 
Health insurance is an attractive option for protecting the poor, as it offers 100% off health 
service costs and 75% off drug costs. Moreover, the cover could last for a period of a few 
years, which reduces targeting and administrative costs. Most FGDs and KI had a good 
opinion of the way that the KHIC is currently offering: although quality of services is not as 
high as the richest group would demand, it appears that access is reasonable and quality 
acceptable. (Not all facilities are accredited to the KHIC: according to the health facility 
survey, approximately 56% of health centres and hospitals accepted patients using health 
insurance, though this may have increased since.) 
 
At present, coverage is low, as members are predominantly salaried: cover for the informal 
sector is optional, and many cannot afford to join. In the household survey, 77% of 
households reported no insurance coverage, while 23% had at least one member with some 
sort of coverage. In terms of the number of individuals covered, out of the total population 
sampled, the proportion was 9.3%. Of these, 49% said they had benefited from health 
insurance during the most recent episode of illness, which means that 4.5% of the total 
population were effectively protected by some type of insurance for this most recent illness. 
The KHIC was the most common insurer, accounting for just under 70% of the insured; the 
next most common was the ‘organised forces’ scheme (21%), individual private policies (4%) 
and employer private policies (1%).  
 
Membership of the KHIC is concentrated in urban poor areas, followed by rural areas. The 
high income areas recorded the lowest level of overall membership. 
 
Health insurance does bring with it the risk of ‘moral hazard’ – that membership inflates use 
of services. Our studies support that, but given the low overall level of health care use in KS 
that may be acceptable. (According to the KHIC reports, average utilisation per member per 
year is 1 visit, which is not high in absolute terms.) In the health facility prescription review, 
37.5% of prescriptions reviewed were from patients using a health insurance scheme.   
Given that overall health insurance coverage across Khartoum State is estimated at 10-20%, 
this figure is higher than expected and indicates that insured patients are more likely to 
access services and drugs. Moreover, an urban bias was found in the prescriptions from 
insured patients, suggesting either that patients are more likely to join if they live in urban 
areas, and/or are more likely to use the urban facilities.   
 
The health facility price checks confirmed that insured patients are being exempted the full 
service costs and 75% of drug costs. 
 
Within the KHIC, there is a flat-rate premium for membership for the indigent, students, and 
martyr’s families of 5,000 SDD (roughly $20) per year. This provides cover for the whole 
family. If we take the estimates from our studies of roughly 20% of households who cannot 
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afford health care, the cost of providing cover for them would be 765 million SDD per year12 
(or around 3 million USD). This figure will decrease if the IDP population relocates to the 
south to any large extent: roughly three-quarters of the total who cannot afford access to 
basic health care, according to our HEA study, are IDP households.  
 
Identification of the target group could be based on the HEA information and eligibility 
established proactively and for a set period of time, to reduce transaction costs. 
 
Sources for funding this free cover could include: 
 Increased budgetary allocations for health, within the State or Federal budget 
 Reallocation of part of the surplus currently being transferred to the KMoH by the RDF, 
which could fund a quarter of these households, at its current rate 
 Using Zakat funds to pay for a portion of these households13 
 Using aid funds to buy insurance, which would be easy to monitor and politically 
acceptable 
 
The advantages of this approach would be: 
 It would target poor households directly, with relatively little leakage to the non-poor, 
providing assistance with all basic health care costs and freeing up household resources 
for other important expenditures 
 It would boost the role of the KHIC, which is providing a good service at present, but 
struggling to increase coverage in the informal sector 
 It would strengthen the RDF, by boosting demand for its products amongst a group which 
is currently unable to pay 
 It does not require any additional structures and keeps administrative costs to a minimum 
 It could be done without diverting resources from other States (this is important given 
Khartoum’s already relatively privileged position). 
 
Extending national exemptions and free programmes  
 
Another option is to extend exemptions and/or the scope of existing free programmes. 
 
It seems that there is no clear official policy on exemptions for those who are unable to pay 
for health care. Of our household survey sample, only two people (out of 167 who were 
unable to pay) reported receiving a free service – one was in the bottom quintile and one in 
the top, suggesting that financial need may not be the main criterion even for this small 
proportion of clients.  
 
In the health facility survey, all hospitals and over 60% of the health centres reported that 
they operated an official exemptions scheme14, with ‘paupers/indigent’ as the main eligible 
                                               
12
 Based on FMoH 2003 population estimate for Khartoum of 5,352,000, divided by five (to gain the 
20%); the resultant 1,070,400 is divided by 7, which is the average number per household, according 
to our HH survey; this is then multiplied by the premium of 5,000 SDD per HH. 
13 In the Khartoum HIC, the Zakat currently sponsors 16,000 families to join. They are selected by a 
local committee out of the 300,000 households (i.e. about 1.5 million people) currently classified by the 
Zakat as poor. They are given HI membership for 5 years, after which their status is re-evaluated.  
 
14
 The term ‘official exemptions’ was defined as exemptions that are systematically and routinely 
applied by a facility.  It does not mean that they used all these exemptions or that the MOH officially 
endorsed them, although some are (e.g. emergency treatment and treatment for patients with TB).    
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group. Hospitals claimed to give full exemptions, while health centres either exempted in full 
or reduced prices to 25%. Other exemption categories included emergency cases and TB 
patients. Some facilities also reported giving unofficial exemptions. (The People’s 
Pharmacies were fully commercial and did not offer any exemptions.) It seems then that 
exemptions do exist, but the reported numbers suggest that they are on a small scale, and 
with considerable facility-level discretion. One urban health centre reported accepting 
payment in kind, and 19% of health centres (but no hospitals) accepted late payment of fees. 
 
At present, some drugs are provided at no cost through vertical programmes, funded by 
donors, such as for EPI and family planning. These services are supposed to be free, but in 
reality our health facility and household surveys suggest that patients are sometimes 
charged for these services.  In the household survey, 5% reported paying for immunisation; 
70% for antenatal care; and 20% for postnatal care.  
 
Although the KMoH claims to operate a single tariff for user fees, we were unable to obtain it 
even from the central offices, and facility visits suggest that there is no system for posting it 
up (fewer than 8% of health centres had notices up, all of these in rural areas). It is no 
wonder then that facility charges were found to differ in an apparently random manner (not 
correlated with facility type, location, rural/urban areas etc.). Lack of consistency increases 
the uncertainty for patients and increases the likelihood of not seeking treatment, being 
unable to pay for drugs and services, and of being vulnerable to informal charging. It should 
be a matter of urgency that drugs and service prices are formally posted in all health facilities 
and People’s Pharmacies. 
 
The Ministry of Finance funds the first 24 hours of drugs for emergency cases in hospitals. 
The RDF delivers these drugs in KS. According to our household survey, 50% of those who 
were had had a recent episode of hospitalisation reported having to pay for their drugs in the 
first 24 hours. How the triage is done between emergency and non-emergency cases is not 
clear. 
 
The IDPs used to benefit from free NGO services, such as the ‘Displaced people’s free 
essential drug project’. These were cut after the UNICEF MICs survey (2000), which was 
interpreted as showing that access was not a major issue. However, as the data was not 
disaggregated by socio-economic group, it is hard to see how conclusions for specific 
groups, such as the IDPs, could be drawn. It led, however, to the withdrawal of funding by 
donors for organisations like Save the Children UK to provide free or highly subsidised 
services. In 2003, there were 214 of such clinics, but many now have to charge for services. 
If aid flows increase post-peace agreement, donors should re-examine the evidence for 
supporting some of these programmes which targeted specific disadvantaged groups.  
 
Although no figures were available, KIs reported that the MoF makes funds available to 
assist with high-cost interventions such as heart operations. Similarly, the Zakat was said to 
be mainly used to pay part of the costs of expensive hospital procedures. While these are 
potentially catastrophic costs, it would be interesting to know which groups are benefiting 
from these funds. There is a risk that better-connected and more knowledgeable individuals 
benefit disproportionately. 
 
                                                                                                                                                   
Unofficial exemptions refer to exemptions that are applied at the discretion of an individual member of 
staff and are not routinely used by the facility.   
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In the absence of greater transparency and uniformity on fees for different services, the 
avenue of investing in exemption is less promising that identifying the poor and providing 
them with access to the whole range of basic care. 
 
Extending community health insurance models 
Sudan experimented with Bamako-style community finance initiatives in the 1990s, but very 
little documentation exists on these, and KI evidence suggests that these schemes have 
either faltered or are operated informally. On this basis, extending community financing does 
not appear to be a significant option for improving access in KS. That is not to underplay the 
role of existing informal mechanisms, which are the main coping strategy for families who 
cannot afford to pay health care costs. 
 
Reforming existing mechanisms, such as the Zakat 
The Zakat system is the only official social security in Sudan. It is based on a mandatory 
deduction of 2.5% of income payroll deduction, which is earmarked for assisting the poor and 
needy. 
 
The system for accessing assistance from Zakat is complicated. First, the householder has 
to go to the People’s Committee in the neighbourhood to get a certificate. If successful, they 
take the certificate to the Zakat office, where it goes to a committee. The committee can send 
an inspector out before deciding whether to help and by how much. Assistance is given on a 
case-by-case basis, so that they may get assistance on one occasion, but not another. 
Clearly this is time-consuming both for the beneficiaries and the officials, and is too complex 
for small items of health expenditure. 
 
The HEA findings were that while some quarter Popular Committees reported the Zakat 
system to be ineffective – with ceilings on numbers of claimants to be referred to the Zakat 
head office and a considerable struggle even for the smallest claim – there appears to be 
considerable variation.  In wealthier Quarters – such as El Shabia – the Zakat committee 
helps more households, and gives each larger sums of money than in poorer quarters.  It 
appears that connections are important.   Most of the FGDs also expressed distrust in the 
local authorities and Popular Committees, which they regarded as biased and dishonest. 
 
It should be noted that many Muslims complained about the Federal government’s 
exploitation of the Zakat system to generate taxes. For them the system of traditional Zakat – 
whereby a rich man contributes to his poor neighbours at a local level – was always more 
effective.  Wealthy people are now doubly taxed – the government’s Zakat system, plus they 
are obliged to help people out locally as well.  The system has turned into a time-consuming 
bureaucratic system of hurdles, which is ineffective and unresponsive to the needs for which 
it was created. 
 
In addition to the compulsory Zakat, a voluntary system, called ‘takaful’, was started up in the 
1990s, whereby wealthier community members donated funds to assist with emergency 
health care needs. 67% of the hospitals in our health facility survey reported having a takaful 
office, but FGDs claimed that these are no longer active, since the 1999 Presidential decree 
made emergency care for the first 24 hours in hospitals free.  
 
Potential improvements to the Zakat could include: 
 Setting clear criteria for assistance, on the basis of low income levels or other 
measurable categories of vulnerability 
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 Simplifying procedures to access assistance  
 Making assistance available for basic health care – not just tertiary care  
 Giving certificates which entitle the holder to assistance for a designated period of time 
(such as 2 years), so that the costs of accessing assistance are reduced 
 Publishing accounts, so as to build confidence in how Zakat funds are used 
 
Increasing central funding and decreasing patient contributions generally 
 
As a result of economic problems, the withdrawal of aid in the early 1990s and the 
liberalisation programme of the late 1980s and early 1990s, Sudan has shifted much of the 
burden of financing health care on to households (with the state funding only 20% of health 
care costs, as opposed to the SSA average of 41%). This is a policy which could be 
modified, with political will and an increase in resources. The potential for increasing the 
public health envelope comes from: 
 The ‘peace dividend’ (an estimated $1 million per day was being spent on defence and 
security – funds which could be released for productive activities after the peace 
agreement) 
 Increased aid, with the ending of the embargo against Sudan 
 Debt forgiveness or rescheduling, subject to agreement with creditors over improved 
governance etc. 
 Increased revenue from oil, now that revenue sharing arrangements with the South have 
been agreed  
 
These factors could permit the Sudanese government to increase its spending on health, 
both at federal and state level, from levels that are low, even by African standards, and to 
either subsidise patient costs at a higher rate across the board, or make a wider range of 
services free, or fund waivers for specific population groups. 
 
The extent to which improvements could be made in existing allocations to the health sector 
is hard to gauge, given the extremely limited information on health financing. However, there 
is evidence that government expenditure is focussed on rural hospitals and tertiary hospitals 
in richer areas. The government only pays for low salaries in primary facilities, and for 
emergency drug funds. Parallel structures exist for the army and police, which offer higher 
quality of care for their members. Although more research is needed in this area, there is 
clear prima facie evidence that changes to the current allocations could improve equity and 
efficiency in the health sector. 
 
 
Options & issues for expansion outside Khartoum 
 
The CMSPO is responsible for the supply of pharmaceuticals throughout Sudan. It procures 
items on the Sudan National List of Essential Drugs and supplies them at a 35% mark-up to 
institutions. The institutions then sell on to clients with a mark-up of their own of 20-25%. The 
CMSPO purchases in bulk from local and overseas manufacturers (including from India and 
China) and is thus able to undercut private suppliers. 
 
In 2002, CMSPO established RDFs in 7 states, rolling out to a further 10 in 2003. The 
experience with roll out has not been documented, though meetings have been held to 
examine successes and weaknesses. Anecdotal evidence suggests that – as one would 
expect – some areas have been successful and others not. The main factors favouring 
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success include leadership and having a strong local economy. Gezira State does well on 
both counts as it is both relatively affluent, and also is led by someone who used to be 
involved with the RDF in Khartoum and is knowledgeable and committed to that model. In 
other (poorer) states, it is less clear whether the RDF is really functioning. 
 
Although the RDF (Khartoum) manager was closely involved with the roll-out to other states 
and provided both advice on and training in the process, there are some significant 
differences in the way that RDFs are being introduced nationally, compared with Khartoum. 
For example: 
 capitalisation is much lower: only 200 million SDD was provided in total for the first 7 
states (against an estimated need for USD 160-400 million for the whole country (Graaff, 
P. & Everard, M., 2003)  
 the process has been very quick, with less time for building capacity and training staff 
 the model is different, with drugs sold to the States’ RDF, to sell on to facilities or 
patients. Thus risk is not held centrally by the CMSPO, but is transferred to the RDFs, 
which may then use the funds in different ways. CMSPO sells its drugs to the States with 
a 12% mark-up and in theory the RDFs are limited to the same mark-up in selling on 
(though they may sometimes exceed this) 
 
The lower population density, lower purchasing power, larger distances and poorer 
infrastructure in many States pose significant problems for the operation of a Khartoum-style 
RDF. 
 
Secondary sources suggest that facility level drug funds which were set up in the 1990s and 
1990s have ceased to function officially, but that individual health workers continue to buy 
and sell drugs, as a profitable side line (ElMuktar, M. & Saad Eldin, M., 2001).  
 
It is recommended that the CPSMO revisits the option of establishing drug funds based on 
the same model as the Khartoum RDF, over time and with adequate support, in the richer 
states. In poorer states, a financially viable RDF is unlikely to work: a programme of free 
drugs distribution would be more realistic and equitable. Further research would be needed 
prior to establishing this, as this study’s data were limited to Khartoum State.  
 
Summary of analysis 
 
This discussion concluded that the RDF has been successful and that it continues to fulfil its 
original mandate, though not without facing some current threats to its financial viability and 
public health role. The high degree of political support, large investment and long start-up 
period with emphasis on systems and training were some of the main factors supporting its 
success, as well as the strong economy of Khartoum. 
 
In terms of the current need for the RDF, most of the original factors which necessitated it 
have changed. Nevertheless a comparison of costs and benefits suggest that the RDF 
continues to deliver value for money, and that in its absence, drug costs to users would rise 
by 50-100%.  
 
Overall access to health facilities and the RDF services is good, but there are considerable 
discrepancies by income group which suggest that pro-poor measures are necessary. These 
could operate through the RDF or through wider mechanisms. A discussion of the 
advantages and disadvantages of various approaches leads us to conclude that extending 
health insurance coverage to disadvantaged groups, increasing the overall health budget, 
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restarting free services for especially disadvantaged areas and improving the administration 
of the Zakat system are the priorities. 
 
Lessons for other areas of Sudan are limited, in that the data gathered here cannot be taken 
as representative outside KS. However, the general evidence suggests that RDFs, run along 
similar lines to the Khartoum RDF, could be equally successful in richer states, while free 
drug distribution programmes are more realistic for the more remote and poorer states. 
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7. Conclusions and recommendations 
 
How the RDF is working at present? Strengths and weaknesses 
 
This evaluation concludes that the RDF is continuing to fulfil its original mandate, to provide a 
sustainable source of appropriate, quality drugs at below-market price levels.  
 
Its strengths can be summarised as follows: 
 It continues to serve the majority of the KMoH network of health centres and hospitals in 
Khartoum State, as well as 18 of the People’s Pharmacies  
 Its price list undercuts rivals by 40% (CMSPO) and 100% (People’s Pharmacies and 
private pharmacies), on average 
 It operates a unitary system, offering the same price to all public facilities, and absorbing 
the financial risks (the RDF sells directly to patients, not to the facilities, except for the 
People’s Pharmacies) 
 It maintains regular supervision and deliveries: drugs availability is good at facility level 
 It offers a wide range of drugs (145 items in total) 
 Assessment of selected rational drug use indicators showed the proportion of patients 
encounters using one or more injection and the number of drugs prescribed per patient to 
be within or very close to optimal levels. 
 It is profitable: gross profits have been rising year on year due to large increases in 
volume of drugs sales 
 The financial review suggests that internal control systems are good 
 Its ratio of assets to liabilities is healthy 
 It has just been through a period of capital expansion, investing in a new office building 
and warehouse 
 Foreign currency availability is no longer a constraint, given the wider economic changes 
in Sudan 
 It makes a regular transfer to the KMoH, worth 210 million SDD per year, which more 
than outweighs the fiscal subsidy of its 17.5% customs tax exemption 
 It offers other public services, such as delivering emergency drugs and vaccines 
 
Set against this are some areas of weakness, or concerns: 
 Profit levels are high; this, while a good thing from a business point of view, may indicate 
that prices to users could be reduced 
 Operating costs have increased substantially in the RDF in 2001-3, especially in the area 
of salaries and incentives 
 The value of expired stock has also increased significantly over this period 
 The build up of stocks means that the working capital cycle has doubled between 2001 
and 2003, which increases the risk of losses 
 The value of debts, particularly from one or two non-paying specialist hospitals, threatens 
the RDF’s ability to pay creditors, which is essential for its continued smooth procurement 
(though this situation is now being improved). 
 Decreases in attendances at RDF facilities and problems with the health insurance 
system have resulted in reduced profits for the past three years. This is a worrying trend. 
 The proportion of RDF sales value which is being transferred to the KMoH has doubled 
over time (at the same time as KMoH contributions, in form of staff salaries, for example, 
have reduced). It is now 17.5 million SDD each month. Excessive extraction is a threat to 
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the RDF’s viability. It is also not clear whether the surplus is being used according to the 
originally agreed purpose of promoting PHC. 
 An absence of capital investment plans is noted, particularly in relation to the current 
development of new offices. 
 There is a need for more details in the recent financial reports, including giving 
explanations for trends. 
 The RDF has suffered from an unfortunate discontinuity of management over the past 
two years, though a permanent director has now been appointed in 2005. Strong 
leadership is essential to continued viability and quality of work. 
 The RDF’s fortune is now strongly connected with the KHIC, which is its major purchaser. 
It also owns shares in the KHIC. Any adverse development for the KHIC would also 
impact on the RDF. It is also dependent for its current profits on its People’s Pharmacy 
network: through 18 outlets it sells more drugs than through its 123 hospitals and health 
centres. 
 Linked to that is the disproportionate growth in sales of non-essential. While driving up 
profits, there is a real risk that the RDF mandate of promoting rational prescribing will be 
overshadowed by this trend. 
 The prescription review suggests that antibiotics use is still too high and has risen since 
the last survey (in 2000). That and the high use of syrups and low use of ORS suggest 
that there is need for more investment in practitioner and consumer education 
 Qualitative information from focus groups show that patient awareness is also low  
 Although availability of essential drugs is still high in facilities, it has dropped from 100% 
in previous surveys to 95% now. 
 The market survey found that for the 15 most commonly used drugs, the CMSPO prices 
undercut the RDF’s – on average by 10%. (Note though that the CMSPO does not sell 
direct to the public: retailers will add 20-35% to these prices, whereas, at least for the 
health centres and hospitals, RDF prices are the prices that users pay.) 
 Although the RDF is supposed to operate a fixed price list, small but significant variations 
in prices were found across the facilities (not correlated to location or any other variable) 
 Poor stock keeping records were found in the health facility survey 
 Public awareness of the RDF and public involvement in CHCs was found to have 
remained at a low level 
 Operations research, which was once seen as a core activity for the RDF, appears to 
have withered 
 
Who is benefiting? 
 
As the RDF operates through all of the main KMoH health centres and hospitals in KS, the 
question of who is benefiting has to be answered by looking at use of the public facilities in 
general. 
 
Overall utilisation trends for the RDF network are positive, rising to 3 out of the 5 million 
people in 2002, though with a small decrease the following year.  
 
Geographic access to the facilities is good: mean time to reach a health centre in the 
household survey was 15 minutes, and 34 to reach a public hospital.  
 
Quality indicators examined in the health facility survey are on the whole positive and 
suggest that quality does not vary systematically by location or rural/urban status, with the 
exception of KMoH supervision, which is more frequent in urban areas. (The full details of the 
health facility findings are published separately (Cadge, N. & Elkarim, Professor M., 2005)). 
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The household survey also reinforces the importance of the public services: the main 
treatment strategy was to go to a health centre (36% overall), followed by public hospitals 
(29% overall). Moreover, these facilities are more important for the poor: use of health 
centres is concentrated in the bottom three quintiles, while hospitals are important to the 
bottom four quintiles, but not the richest. 
 
Financial barriers are, however, significant. Since the liberalisation and health sector reforms 
of the 1990s, Sudan has placed a heavy burden of paying for health care on households, 
with the state contributing a mere 20% (one of the lowest proportions in Africa). Of these 
household costs, drugs form 58% of the total, according to our household survey. 
 
According to the HEA, 17% of Khartoum State’s population is unable to afford basic health 
care for all or part of the year. This group is concentrated in the IDPs – 60-75% of IDP 
households fall into this category, compared with 5-10% for the rural and urban poor. A 
further 24% overall is estimated to be unable to afford emergency health care without 
assistance (22% in urban areas; 30% in IDP areas; and 30% in rural areas). 
 
In the household survey, 6% opted for no treatment (with lack of money the predominant 
factor), while 29% of those who sought treatment could not afford to pay for it. For the more 
disadvantaged groups, inability to pay is, of course, higher: within IDP areas, 46.5% could 
not afford to pay, while for the bottom quintiles, the proportion is 32-37%. Moreover, 
households in the poorest quintile are five times more likely not to treat sick members, 
compared with the top quintile.  
 
Overall, health expenditure as a proportion of household income is 11%, which is high by 
international standards. The differences between areas were not statistically significant, but 
the group with the highest proportion were the IDPS, who were found to be spending 15% of 
their total household income on health care. 
 
For those who cannot afford to pay, borrowing is the main coping strategy across the social 
groups (57% overall), which reinforces qualitative information on the importance of informal 
social networks. 
 
Formal support systems were found to exist, but to be limited in scale, arbitrary and difficult 
to access. Exemptions policies vary by facility and only 1% reported receiving them. 3% of 
those who were unable to pay reported receiving charitable donations and 3% reported 
assistance from the Zakat (the official Muslim social support fund). FGDs reported bias in 
allocating assistance from the Zakat, favouring those with better contacts.  
 
Options for expanding access within Khartoum 
 
Given that the main barriers to accessing the RDF are financial, any measure which reduces 
household costs (for vulnerable groups) or increases their income will increase access. The 
potential range of actions is therefore wide. 
 
Providing internal subsidies within the RDF is one option, but given the need for the RDF to 
maintain its viability, there is limited scope for this. Besides, the aim should be to increase 
access to health care generally, rather than encouraging self-prescription. It is therefore 
preferable to extend health insurance cover to those who cannot currently afford to access 
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basic care. The health insurance network and quality is adequate, and this measure would 
boost its development, as well as increasing business for the RDF, at low administrative 
costs. 
 
Given current Khartoum Health Insurance Corporation (KHIC) premia, to provide 
membership for 20% of KS population would cost in the region of USD 3 million per year. 
This could be funded from a number of sources, including State budgets; the RDF ‘surplus’, 
which it pays monthly to the KMoH; the Zakat (which does fund some poor households to 
join at present, but on a limited scale); and aid flows, which should increase post-peace 
agreement. Identification of beneficiaries could be carried out using the HEA information. 
 
Given that so many of the households which are excluded are IDP15 ones, an alternative 
would be to restart the free services which used to exist in IDP areas, but which were closed 
earlier this decade, once conditions were thought to have improved. (This will prove complex 
if IDPs are dispersed amongst the host community, however.) 
 
Another option which would assist both IDPs and other poor and vulnerable residents would 
be to improve the administration of the Zakat, so that it becomes available on a larger scale, 
with clear criteria for access, lower access costs, and greater transparency and 
accountability. 
 
‘Peace dividend’ funds should also be used to increase the overall public contribution to 
health care and so enable user fees in public facilities to be reduced. Some areas could be 
declared exempt as a region, on the basis of widespread poverty. Closer analysis of health 
spending at all levels would also identify areas where resources could be shifted to increase 
equity and efficiency. There is more detail on these recommendations in our household 
survey report (Witter, S. & Babiker, M., 2005).  
 
Other measures to support the income of vulnerable groups include: changes to the 
replanning process, to reduce costs for IDPs; income generation activities aimed at boosting 
and diversifying income in IDP areas; and development of infrastructure in outlying areas 
(rural as well as IDP settlements) to enhance access to markets. The HEA report provides 
more detailed recommendations on these areas (Adams, L. & et al., 2004). 
 
Issues for national expansion 
 
Lessons for other areas of Sudan are limited, in that the data gathered here cannot be taken 
as representative outside Khartoum State, given the large differences in infrastructure and 
income levels. However, the general evidence suggests that RDFs, run along similar lines to 
the Khartoum RDF, could be equally successful in richer states, while free drug distribution 
programmes are more realistic for the more remote and poorer states. 
 
Research gaps 
 
                                               
15
 IDPs are families who have fled from conflict and economic hardship, mainly in the south and west 
of Sudan, to live in the Khartoum area. Although many have been there for two decades, they 
continue to be classified as IDPs. In the wake of the Comprehensive Peace Agreement in 2005, many 
are returning to their home areas, particularly in the south. It is not clear how many of the 2 million will 
remain as residents of Khartoum State. 
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Given the interest in expanding the RDF model to other States, a systematic evaluation of 
the CMSPO roll-out to date should be conducted. This is the second attempt, in that Bamako 
Initiative-style drug funds were set up at local level in the 1990s. Documentation of that 
experience is also lacking. 
 
Recommendations 
 
The RDF should continue to provide its services for Khartoum and to enjoy political support 
and independent status. However, there are significant findings which need to be acted on, 
internally and externally. 
 
Recommendations for the RDF management  
 
The policy on salaries and incentives needs to be reviewed, so that this type of expenditure 
does not spiral out of control. 
 
The RDF management should investigate the causes behind the following issues which have 
been raised, and propose a plan for continuing to address them: 
 Increase in expired stocks in facilities 
 Poor stock record keeping in some facilities 
 Fall in availability of essential drugs  
 Small but significant variation in prices charged for drugs by facilities 
 
The policy of subsidising more expensive drugs should be reviewed: what are the equity 
implications of this? 
 
The management should discuss an informal cap on gross profits at around 15%, to 
minimise costs to users while maintaining adequate funds for reinvestment. (This cap could 
be lifted for exceptional circumstances, such as infrastructure expansion, but would be 
regarded as a norm, with justification required for increases.) 
 
In addition to providing routine data, the RDF should focus on questions of importance for its 
overall function and carry out appropriate action research relating to these. These need not 
be ambitious or expensive, but would encourage a culture of reflection and goal-orientation: 
the RDF should continue to see itself as more than a business - as a role to pay in promoting 
good health generally. 
 
Related to that is the need for renewed practitioner and client education on rational drugs 
use (in particular, to reduce the proportion of antibiotics being prescribed). This should be 
carried out in partnership with the KMoH Department of Pharmacy. Financial incentives to 
increase sales should be reviewed to ensure that they do not promote irrational prescribing. 
In this respect, it would be worth monitoring the proportion of essential/non-essential sales 
through People’s Pharmacies, as well as keeping a downward pressure on the sale of brand 
name drugs through these channels. The public demand and growth in insured patients is 
creating an upward pressure on expenditure, which is not in the public interest. 
 
The RDF and KMoH should together develop a plan to address the drugs supply to smaller, 
more remote health centres. This may require some medication of the RDF’s systems – for 
example, by allowing longer intervals between supply and supervision visits.  
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The RDF should review its procurement practice, to ensure that it is getting the right balance 
of quality and price. 
 
The relationship with non-paying debtors, such as the Cardiac Unit, which is in the process of 
being resolved, should not be allowed to recur. 
 
The donated fixed assets should be re-valued, included in the financial records, and 
depreciated on an annual basis. 
 
Format of annual financial statements must continue to be in accordance with the 
international accounting standards and reporting standards, and approved by all the 
stakeholders. 
 
Ministry of Health 
 
The KMoH should review the amounts that it is being paid monthly by the RDF: the current 
level seems unduly high and may be one of the factors behind the build up of creditors. 
Payments should be suspended or reduced, at least until RDF creditors have been paid in 
full.  
 
The KMoH should investigate the causes behind the documented drop in supervision, 
especially to rural health centres, and other quality issues raised in the health facility report. 
 
The low levels of utilisation of public facilities documented in the health facility report and 
also indicated in the declining attendances at RDF facilities (other than PPs) should also be 
addressed in partnership by the RDF and KMoH. Strategies here could include 
improvements in hours worked by health staff and public education on the efficacy of generic 
drugs. 
 
The user fee tariff should be made flatter and more transparent, with better posting of prices 
in health facilities. 
 
The KMoH should work with the FMoH to ensure that additional barriers to importation and 
clearance of drugs are not created and that the RDF is facilitated in carrying out its work 
efficiently. 
 
There is a need for the FMoH and KMoH to review the NEDL, to ensure that it is up-to-date 
with current prescribing practice. 
 
Government and donors 
 
The burden of paying for health care falls heavily on households at present in Sudan, 
compared with other developing countries. The GoS should use ‘peace dividend’ funds to 
increase its overall contribution to health care, thus reducing the burden of cost recovery, 
particularly in the poorer States. 
 
Donors should study the case for reinstating free programmes, which used to benefit 
vulnerable groups, such as the IDPs in Khartoum State. 
 
 
 
 
 
 
 
 
 
Khartoum Revolving Drug Fund: sustainability and access 
Witter et al. 2005 
74 
Measures to support IDP incomes and access to infrastructure should be taken to improve 
access to health care, among other goods. 
 
The operation of the Zakat needs to be reviewed: it is currently viewed as ineffectual due to 
complex procedures, perceived favouritism, and lack of transparency. 
 
Measures to improve access to health care and drugs should include the provision of KHIC 
membership to vulnerable households in Khartoum State.  
 
Further research is needed to for health financing in Sudan generally, as well as more 
specifically on expenditures at State level and the operation of RDFs outside Khartoum. 
These will inform decisions on the overall budget for health and also maximising the use of 
existing resources. 
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Annexe 3. Market survey results  
 
Ser 
No 
Drug Name Privat
e 
Pharm 
in 
SDD 
Popul 
Pharm 
in 
SDD 
CMS 
in 
SDD 
 
RDF 
in 
SDD 
Priv/ 
RDF 
Pop/
RDF 
CMS
/RDF 
Priv/
CMS 
1 Diazepam Tabs 5mg 237 101 75 30 7.9 3.4 2.5 3.2 
2 Diazepam Inj 25mg 86 150 25 30  2.9 5.0 0.8 3.4 
3 Promethicizine Tabs 
25mg 
116 85 - 50 2.4 1.7 - - 
4 Promethicizine Inj 
50mg 
82 75 26 50 1.6 1.5 0.5 3.1 
5 Acetyl salicylic acid 
300mg 
98 65 15 15 6.5 4.3 1.0 6.5 
6 Acetyl salicylic acid 
100mg 
69 64 - - - - - - 
7 Ibuprofen Tabs 
200mg 
98 98 40 68 1.4 1.4 0.6 2.5 
8 Ibuprofen syrup 566 403 - - - - - - 
9 Paracetamol Tab 46 48 20 20 1.5 1.6 0.3 2.3 
10 Paracetamol syrup 218 237 110 130 1.2 1.8 0.8 2.0 
11 Indomethacin Caps 
25mg 
121 112 - 68 1.8 1.6 - - 
12 Chloroquine Tabs 86 98 50 50 1.7 2.0 1.0 1.7 
13 Chloroquine syrup 254 259 170 125 2.8 2.1 1.4 1.5 
14 Chloroquine inj 42 48 38 35 1.2 1.4 1.1 1.1 
15 Chlorophenarmine 
Tabs 
71 86 35 50 1.4 1.7 0.7 2.0 
16 Chlorophenarmine 
syrup 
320 323 180 - - - - 1.8 
17 Chlorophenarmine inj 83 92 35 50 1.2 1.8 0.7 2.4 
18 Dexamethazone inj 106 88 20 - - - - 5.3 
19 Hydrocortizone inj 397 225 175 200 2.0 1.1 0.9 2.3 
20 Hydrocortizone 
cream & ointment 
486 504 170 - - - - 2.9 
21 Prednisolone Tabs 110 100 90 - - - - 2.2 
22 Carpamezapine Tabs 359 260 75 - - - - 4.8 
23 Carpamezapine 
syrup 
1354 942 - - - - - - 
24 Phenythion Tabs 705 500 70 - - - - 10.1 
25 Phenobarbitone Tabs 92 83 90 - - - - 1.0 
26 Mebendazole Tabs 255 288 - 50 5.1 5.8 - - 
27 Mebendazole syrup 381 458 - 200 1.9 2.3 - - 
28 Prazaquantel Tabs 434 483 230 200 2.2 2.4 1.2 1.9 
29 Amoxicillin Caps 
250mg 
117 158 75 100 1.2 1.6 0.8 1.6 
30 Amoxicillin Caps 
500mg 
258 283 150 - - - - 1.7 
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31 Amoxicillin syrup 
125mg 
347 410 160 200 1.7 1.6 0.8 2.2 
32 Amoxicillin syrup 
250mg 
496 400 225 250 2.0 1.6 0.9 2.2 
33 Benzyl penicillin inj 46 50 30 40 1.2 1.3 0.8 1.5 
34 Procaine penicillin inj 50 50 30 40 1.3 1.3 0.8 1.3 
35 Ampicillin + cloxacillin 
caps 
256 275 205 218 1.2 1.3 0.9 1.2 
36 Ampicillin + cloxacillin 
syrup 
451 464 325 350 1.3 1.3 0.9 1.4 
37 Tetracycline Caps 75 78 50 35 2.1 2.2 1.4 1.5 
38 Tetracycline skin 
ointment 
168 225 75 - - - - 2.2 
39 Tetracycline eye 
ointment 
93 103 50 75 1.2 1.4 0.7 1.9 
40 Chloramphenicol 
caps 
233 233 80 - - - - 2.9 
41 Tetracycline ear-eye 
drops 
365 356 125 150 2.4 2.4 0.8 2.9 
42 Ciprofloxacin Tabs 
500mg 
1471 1310 600 - - - - 2.5 
43 Ciprofloxacin Tabs 
250mg 
675 702 275 - - - - 2.5 
44 Erythromycin Tabs 
250mg 
248 286 205 175 1.4 1.6 1.2 1.2 
45 Erythromycin syrup 
125mg 
516 475 300 300 1.7 1.6 1.0 1.7 
46 Erythromycin syrup 
250mg 
811 817 510 - - - - 1.6 
47 Second generation 
cephalosporin(ceftazi
dime inj) 
1858 1667 1200 - - - - 1.5 
48 Third generation 
cephelosporin(ceftazi
dime inj) 
1893 1500 - - - - - - 
49 Ampicillin + cloxacillin 
inj 
184 203 60 150 1.2 1.4 0.4 3.1 
50 Metronidazole Tabs 
250mg 
77 53 27 29 2.7 1.8 0.9 2.9 
51 Metronidazole I.V. 464 488 480 450 1.0 1.1 1.1 1.0 
52 Metronidazole syrup 447 281 200 200 2.2 1.4 1.0 2.2 
53 Gentamycin inj 161 106 60 50 3.2 2.1 1.2 2.7 
54 Gentamycin eye-ear 
drops 
411 381 100 - - - - 4.1 
55 Co-trimoxazole Tabs 160 170 45 50 3.2 3.4 0.9 3.6 
56 Co-trimoxazole syrup 541 403 150 150 3.6 2.7 1.0 3.6 
57 Acyclovir Tabs 
200mg 
3079 2100 - - - - - - 
58 Acyclovir skin 2112 2258 - - - - - - 
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ointment 
59 Acyclovir eye 
ointment 
4223 4600 - - - - - - 
60 Rifampicin 300mg 343 - 200 - - - - 1.7 
61 Pyrazinamide Tabs 238 100 80 - - - - 3.0 
62 Streptomycin Tabs 57 50 35 30 1.9 1.7 1.2 1.6 
63 Nystatin oral drops 454 663 - - - - - - 
64 Nystatin ointment 535 650 - - - - - - 
65 Clotrimazole eye 425 539 - - - - - - 
66 Clotrimazole 
suppositories 
590 625 - 100 5.9 6.3 - - 
67 Ketoconazole Tabs 1385 1028 - - - - - - 
68 Sulphadoxin + 
Pyrimethamin Tabs 
262 150 42 50 5.2 3.0 0.8 6.2 
69 Quinine Tabs 219 180 130 165 1.3 1.1 0.8 1.7 
70 Quinine inj 68 113 75 75 0.9 1.5 1.0 0.9 
71 Artmether inj 2135 1871 900 - - - - 2.4 
72 Fermous Tabs 107 41 50 17 6.3 2.4 2.9 2.4 
73 Fermous syrup 761 842 350 350 2.2 2.4 1.0 2.2 
74 Fermous inj 1457 1425 800 - - - - 1.8 
75 Folic acid Tabs 61 53 50 17 3.6 3.1 2.9 1.2 
76 Atenolol Tabs 50mg 397 478  - - - - - 
77 Atenolol Tabs 100mg 507 544 - - - - - - 
78 Propranolol 40mg 111 125 25 67 1.7 1.8 0.4 4.4 
79 Propranolol 10mg 176 173 - - - - - - 
80 Nifdipine 10mg 254 232 - - - - - - 
81 Nifdipine 20mg 441 388 - - - - - - 
82 Captopril 25mg 618 583 - - - - - - 
83 Amlodipine 5mg 790 574 - - - - - - 
84 Methyl dopa 250mg 335 258 175 117 2.8 2.2 1.5 1.9 
85 Digoxin Tabs 340 319 400 33 10.3 9.7 12.1 0.9 
86 Vitamin K inj 197 131 75 - - - - 2.6 
87 Betamethazone 
ointment + cream 
534 506 - - - - - - 
88 Betamethazone eye 
ear drops 
700 1200 - - - - - - 
89 Furesamide Tabs 198 154 80 23 8.6 6.7 3.5 2.5 
90 Furesamide inj 98 75 35 30 3.3 2.5 1.2 2.8 
91 Spironolactone Tabs 
25mg 
373 419 - - - - - - 
92 Ranitidine 617 618 125 - - - - 5.0 
93 Cimetidine inj 370 375 350 - - - - 1.0 
94 Omeprzole Caps 
20mg 
2152 2327 600 - - - - 3.6 
95 Anti acid Tabs 71 75 50 50 1.4 1.5 1.0 1.4 
96 Anti acid suspension 448 406 330 - - - - 1.1 
97 Metoclopramide 103 119 85 50 2.1 2.4 1.7 1.2 
98 Metoclopramide inj 129 119 - 50 2.6 2.4 - - 
99 Hyoscine Tabs 173 160 85 70 2.4 2.3 1.2 2.1 
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100 Hyoscine inj 80 92 50 50 1.6 1.8 1.0 1.6 
101 Bisacodyl 
Tabs(laxative) 
135 140 - 50 2.7 2.8 - - 
102 Loperamide 
Tabs(Anti diareah) 
230 175 - 50 -4.6 3.5 - - 
103 Oral rehyderation 
powder 
75 58 - - - - - - 
104 Combine 
bills(contraceptives) 
889 767 - - - - - - 
105 Mini 
bill(contraceptive) 
594 610 - - - - - - 
106 Insulin soluble 2683 2750 2600 1900 1.4 1.4 1.4 1 
107 Insulin zinc 2750 2750 2600 1900 1.4 1.4 1.4 1.1 
108 Insulin mixed 2617 2633 2600 2000 1.3 1.3 1.3 1 
109 Glibenclamide 221 135 50 67 3.3 2 0.7 4.4 
110 Metformin 289 288 - - - - - - 
111 Carbimazole Tabs 142 116 - - - - - - 
112 Thyroxine Tabs 
100mg 
571 467 350 300 1.9 1.6 1.2 1.6 
113 Anti tetanus inj 310 325 - - - - - - 
114 Pilocarpine eye drops 
2% + 4% 
989 917 - - - - - - 
115 Timilot eye drops 
0.5% + 0.255 
911 1142 250 - - - - 3.6 
116 Antistine eye drops 390 4166 - - - - - - 
117 Salbutamol Tabs 119 116 25 33 3.6 3.5 0.8 4.8 
118 Salbutamol inj 915 1900 450 - - - - 2 
119 Salbutamol syrup 451 517 200 20 22.6 25.9 10 2.3 
120 Aminophilline Tabs 492 - 300 50 9.8 - 6 1.6 
121 Steroid inj 1691 2250 - - - - - - 
122 Expectorant cough 
syrup 
329 435 220 - - - - 1.4 
123 Anti tissue cough 
syrup 
426 388 200 - - - - 2.1 
124 Mucolytic syrup 727 713 - - - - - - 
125 Chloropromazine 
Tabs 50mg 
208 108 75 - - - - 2.8 
126 Chloropromazine 
Chloropromazine inj 
120 83 50 - - - - 2.4 
127 Amitriplatine Tabs 
25mg 
133 203 130 - - - - 1 
128 Imipramine Tabs 
25mg 
193 117 - - - - - - 
129 Normal saline 
infusion 
276 281 250 250 1.1 1.1 1 1.1 
130 Glucose with water 
infusion 
276 281 250 250 1.1 1.1 1 1.1 
131 D.N.S. infusion 291 281 250 250 1.2 1.1 1 1.2 
132 Water for inj 21 281 15 20 1.1 14.1 0.8 1.4 
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133 Disposable syringes 
5cc 
24 25 20 20 1.2 1.3 1 1.2 
134 Disposable syringes 
2cc 
24 25 20 20 1.2 1.3 1 1.2 
135 Disposable syringes 
1cc 
26 28 20 25 1 1.1 0.8 1.3 
136 Gauze small 60 50 - - - - - - 
137 Gauze long 235 88 - - - - - - 
138 Anti septic solution 502 225 - - - - - - 
139 Local anesthetic inj 310 350 200 20 15.5 17.5 10 1.6 
140 Local anesthetic with 
adrenaline 
350 400 310 80 4.4 5 3.8 1.1 
141 Local anesthetic with 
ointment 
1650 1200 - - - - - - 
142 Nasal decongestant 481 347 - - - - - - 
143 Multivitamin caps 435 340 50 50 8.7 6.8 1 8.7 
144 Total(Average) 510(3
38) 
513(3
21) 
242(2
32) 
171 2.0 1.9 1.4 1.5 
 
